EP1636205A1 - Pyridinyl carbamates as hormone-sensitive lipase inhibitors - Google Patents

Pyridinyl carbamates as hormone-sensitive lipase inhibitors

Info

Publication number
EP1636205A1
EP1636205A1 EP04736303A EP04736303A EP1636205A1 EP 1636205 A1 EP1636205 A1 EP 1636205A1 EP 04736303 A EP04736303 A EP 04736303A EP 04736303 A EP04736303 A EP 04736303A EP 1636205 A1 EP1636205 A1 EP 1636205A1
Authority
EP
European Patent Office
Prior art keywords
methyl
ester
phenyl
pyridin
carbamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04736303A
Other languages
German (de)
French (fr)
Inventor
Johannes Cornelis De Jong
Poul Jacobsen
S Ren Ebdrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1636205A1 publication Critical patent/EP1636205A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel substituted pyridinyl carbamates, to pharma- ceutical compositions comprising these compounds, to the use of these compounds as pharmaceutical compositions, and to methods of treatment employing these compounds and compositions.
  • the present compounds show inhibition of hormone sensitive lipase. As a result, the compounds are useful for the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase.
  • the overall energy homeostasis of a mammalian system requires a high degree of regulation to ensure the availability of the appropriate substrate at the appropriate time.
  • Plasma glucose levels rise during the post-prandial state, to return to pre-prandial levels within 2-3 hours. During these 2-3 hours, insulin promotes glucose uptake by skeletal muscle and adipose tissue and decreases the release of free fatty acids (FFA) from adipocytes, to ensure that the two substrates do not compete with each other.
  • FFA free fatty acids
  • HSL Hormone-sensitive lipase
  • adipocytes HSL catalyses the conversion of triglycerides to glycerol and fatty acids. It is through the regulation of this enzyme that the levels of circulating FFA are modulated. Insulin leads to the inactivation of HSL with a subsequent fall in plasma FFA levels during the post-prandial state, followed by the activation of the enzyme when the insulin concen- tration falls and catecholamines rise during the post-absorptive period.
  • HSL The activation of HSL leads to an increase in plasma FFA, as they become the main source of energy during fasting.
  • the activation-inactivation of HSL is primarily mediated through the cAMP-protein kinase A and AMP-dependent kinase pathways.
  • cAMP-protein kinase A a cAMP-protein kinase A and AMP-dependent kinase pathways.
  • nicotinic acid and its derivatives that decrease the activation of HSL via these pathways and cause a decrease in lipolysis that leads to a reduction in the FFA levels.
  • These drugs have a beneficial effect in the utilization of glucose and in the normalization of the excess triglyceride synthesis seen in patients with elevated FFA. However, since these pathways are used by other processes in the body, these drugs have severe side effects.
  • HSL inhibitors WO 01/87843, WO 01/17981, WO 01/66531, WO 01/83497, and WO 01/26664.
  • HSL inhibitors disclosed in these publications contain pyridinyl and carbamate substructures as in the compounds of the present invention.
  • potent pyridinyl carbamate compounds that specifically inhibit the lipolytic activity of HSL and which may be expected to decrease plasma FFA levels. These compounds can be used to treat disorders where a decreased level of plasma FFA is de- sired, such as insulin resistance, syndrome X, dyslipidemia, abnormalities of lipoprotein metabolism.
  • One object of the present invention is to provide compounds and pharmaceutical compositions that inhibit the lipolytic activity of HSL.
  • a further object is to provide compounds which have good pharmaceutical properties such as solubility, bioavailability, specificity etc.
  • halogen in the present context designates an atom selected from the group consisting of F, Cl, Br and I.
  • C 1-6 -alkyI in the present context designates a saturated, branched or straight hydrocarbon group having from 1 to 6 carbon atoms.
  • C 2-6 -alkyI in the present context designates a saturated, branched or straight hydrocarbon group having from 2 to 6 carbon atoms.
  • Representative examples in- dude but are not limited to, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, ferf-butyl, n- pentyl, isopentyl, neopentyl, ferf-pentyl, n-hexyl, isohexyl and the like.
  • C 1-6 -alkoxy in the present context designates a group -O-C-i- ⁇ -alkyl wherein d- 6 -alkyI is as defined above.
  • Representative examples include, but are not limited to, meth- oxy, ethoxy, n-propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, ferf-butoxy, n-pentoxy, isopentoxy, neopentoxy, terf-pentoxy, n-hexoxy, isohexoxy and the like.
  • C 2-6 -alkenyl as used herein, represent an olefinically unsaturated branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2- propenyl, allyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like.
  • C 3-10 -cycloalkyl as used herein represents a saturated mono-, bi-, tri- or spirocarbocyclic group having from 3 to 10 carbon atoms.
  • Ca ⁇ -heterocyclyl represents a saturated 3 to 8 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur.
  • Representative examples are pyrrolidyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, azirid- inyl, tetrahydrofuranyl and the like.
  • aryl represents a carbocyclic aromatic ring system being either monocyclic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenylenyl and the like.
  • Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic aromatic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1 ,2,3,4-tetrahydronaphthyl, 1 ,4-dihydronaphthyl and the like.
  • heteroaryl represents a heterocyclic aromatic ring system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1 ,2,3-triazoIyl, 1 ,2,4- triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,2,3-triazinyl, 1 ,2,4-triazinyl, 1 ,3,5- triazinyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,3- thiadiazolyl, 1 ,2,4-thiadia
  • Heteroaryl is also intended to include the partially hydrogen- ated derivatives of the heterocyclic systems enumerated above.
  • Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, 3,4-dihydroisoquinolinyl, pyrrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like.
  • perhalomethyl designates a methyl moiety substituted with three halogen atoms.
  • Non-limiting examples of perhalomethyl are CF 3 , CCI 3 , and CF 2 CI.
  • perhalomethoxy designates a perhalomethyl linked via an oxygen atom, e.g. -0-CF 3 , -0-CCl 3 , and -0-CF 2 Cl
  • ring system includes aromatic as well as non-aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and they encompass moieties with zero, one or more hetereatoms selected from nitrogen, oxygen and sulphur.
  • Non-limiting examples of such ring systems are aryl, C 3 ⁇ -heterocyclyl and heteroaryl.
  • heterocyclic system as used herein includes aromatic as well as non- aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and containing in their ring structure one or more heteroatoms selected from nitrogen, oxygen and sulfur.
  • Non- limiting examples of such heterocyclic systems are C 3-8 -heterocyclyl and heteroaryl.
  • the term "optionally substituted” as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent the substituents may be the same or different.
  • the terms "disease”, “condition” and “disorder” as used herein are used interchangeably to specifiy a state of a patient which is not the normal physiological state of man.
  • treatment as used herein means the management and care of a patient having developed a disease, condition or disorder, as well as the management and care of an individual at risk of developing the disease, condition or disorder prior to the clinical onset of said disease, condition or disorder.
  • treatment is to combat the disease, condition or disorder, as well as to to combat the development of the disease, condition or disorder.
  • Treatment includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the dis- ease, condition or disorder.
  • effective amount means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment.
  • modulate means to influence, i.e. to modulate a parameter means to influence that parameter in a desired way. Examples are to modulate insulin secretion from beta cells and to modulate the plasma level of free fatty acids.
  • medicament means a pharmaceutical composition suitable for administration of the pharmaceutically active compound to a patient.
  • pharmaceutically acceptable means suited for normal pharmaceutical applications, i.e. giving rise to no adverse events in patients etc.
  • the present invention relates to a compound of the general formula (I)
  • R 1 and R 2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, amide, urea, thiourea, benzamide, thioamide, halogen, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, amino, amide, urea, thiourea, benzamide, thioamide, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, het- eroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, thio
  • R 3 , and R 4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl and C 3-1o -cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -CyClOaIkYl, wherein
  • R 2 is selected from hydrogen, hydroxy, amino, halogen, Ci -6 - alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C ⁇ -heterocyclyl, amide, urea and thiourea and C 3-10 -CyClOaIRyI, wherein each of hydroxy, amino, C 1-6 -aikyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3 ⁇ -heterocyclyl, amide, urea and thiourea and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C
  • R 4 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 - alkenyl, wherein each of C 1-6 -alkyl, C 2-6 -alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, Cs- ⁇ -heterocyclyl and C ⁇ o-cycloalkyl.
  • R 4 is selected from hydrogen, halogen and C 1-6 -alkyl.
  • R 4 is hydrogen
  • R 4 is halogen
  • R 3 is selected from hydrogen, hydroxy, halogen, C 1-6 -alkyl, C 2-6 -alkenyl, wherein each of hydroxy, C 1-6 -alkyl, C 2-6 -alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C 1-6 -alkyl, C 2-6 - alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl.
  • R 3 is selected from halogen, C 1-6 -alkyl, methoxy, perha- lomethyl and perhalomethoxy.
  • R 3 is selected from halogen, methyl, ethyl, isopropyl, meth- oxy and perhalomethyl.
  • R 3 is selected from halogen, methyl, methoxy and perhalomethyl.
  • the present invention relates to a compound of the general for- mula (I) : wherein
  • R 1 and R 2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, amide, urea, thiourea, halogen, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and wherein each of hydroxy, sulfanyl, amino, amide, urea, thiourea, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2 -6-alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci -alkyl, C 1-6 -alkoxy, C 2 .
  • R 3 , and R 4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, d- 6 -alkyl, C 2-6 -aIkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C 1-6 -aIkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl and Cs-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycIoalkyl,
  • R 2 is selected from hydrogen, hydroxy, amino, halogen, C 1-6 - alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, amide, urea and thiourea and C 3-10 -cycloalkyl, wherein each of hydroxy, amino, Ci -6 -alkyl, Ci -6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, amide, urea and thiourea and C 3-10 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, Cs- ⁇ -hetero
  • R 2 is halogen or hydrogen.
  • R 4 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 - alkenyl, wherein each of C 1-6 -alkyl, C 2-6 -alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C 1-6 -alkyl, C 2- 6-alkenyl, aryl, het- eroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl.
  • R 4 is selected from hydrogen, halogen and C 1-6 -alkyl.
  • R 4 is hydrogen. ; In another embodiment R 4 is halogen.
  • R 3 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 - alkenyl, wherein each of , d -6 -alkyl, C 2-6 -alkenyI is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, het- eroaryl, Cs-s-heterocyclyl and In another embodiment R 3 is selected from halogen, d- ⁇ -alkyl, perhalomethyl and perhalomethoxy.
  • R 3 is selected from halogen, methyl, ethyl, isopropyl and perhalomethyl.
  • R 3 is selected from halogen, methyl or perhalomethyl.
  • the present invention relates to a compound of the general formula (I) :
  • R 1 and R 2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 - cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C 3- i 0 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl,
  • the present invention is related to a compound of the general formula (I)
  • R 2 is H and R 1 is
  • each R 5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci -6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C ⁇ s-heterocyclyl and C 3-10 -cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 - alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8
  • R 3 , and R 4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, Ci -6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl and C 3-10 -cycloalkyl is optionally substituted with one or more substituents inde- pendently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3 .
  • each of hydroxy, sulfanyl, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, Ci -6 -alkyl, perhalomethyl and perhalomethoxy;
  • Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
  • the present invention is related to a compound of the general formula (I) :
  • R 2 is H and R 1 is
  • each R 5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2- e-alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, Ci_ 6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3 - 8 -heterocyclyl and C 3- i 0 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci -6 - alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl,
  • R 3 , and R 4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, C 1-6 -aIkyl, C 2-6 -alkenyl, aryl, heteroaryl, Cs ⁇ -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C 1-6 -alkyl, C 2- 6-alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl and C 3- i 0 -cycIoalkyl is optionally substituted with one or more substituents inde- pendently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl, Cs- ⁇ -heterocyclyl and C 3- i 0 -cycl
  • Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
  • the present invention is related to a compound of the general formula (I) :
  • R 2 is H and R 1 is
  • each R 5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci -6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3 ⁇ -heterocyclyl and C 3 .
  • each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyl, C 1-6 -aIkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl and C 3- i 0 -cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 - alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, C 3-8
  • R 3 , and R 4 are hydrogen
  • the present invention is related to a compound of the general formula (I) :
  • R 2 is H and R 1 is
  • each R 5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci -6 -alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C ⁇ -heterocyclyl and C 3-10 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 - alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs-s-heterocycl
  • R 3 , and R 4 are hydrogen
  • Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
  • the present invention is related to a compound of the general formula (I) :
  • R 2 is H and R 1 is
  • each R 5 is independently selected from hydrogen, hydroxy, amino, halogen, C 1-6 -alkyl, C 1-6 - alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and Ca-io-cycloalkyl, wherein each of hydroxy, d -6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 - cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyI, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and Ca.-m-cycloalkyl,
  • R 3 and R 4 are hydrogen
  • the present invention is related to a compound of the general formula (I)
  • R 2 is H and R 1 is
  • each R 5 is independently selected from hydrogen, hydroxy, amino, halogen, C 1-6 -alkyl, C 1-6 - alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs- ⁇ -heterocyclyl and C M o-cycloalkyl, wherein each of hydroxy, amino, C 1-6 -alkyl, Ci -6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C 3- 10 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci -6 -alkyl, Ci -6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C ⁇ -heterocyclyl, and C 3-10 -cycloalkyl,
  • R 3 and R 4 are hydrogen
  • Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
  • the invention is related to a compound wherein R 2 is selected from from hydrogen, hydroxy, amino, halogen, Ci -6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl and C 3-10 -cycloalkyl, wherein each of hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 - alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3-10 -cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3 ⁇ -heterocyclyl, and C 3-10 - cycloalkyl, where
  • the invention is related to a compound wherein R 3 is selected from fluor, chlor, methyl, perhalomethyl or perhalomethoxy.
  • the invention is related to a compound wherein R 2 is hydrogen. In another embodiment the invention is related to a compound wherein R 2 is selected from the group consisting of
  • R 2 is selected from the group consisting of
  • each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, d-e-alkyl, C 1-6 -alkoxy, C 2 -6-alkenyl, aryl, heteroaryl, C 3 ⁇ -heterocyclyl, and C 3-10 -CyClOaIRyI, wherein each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C 3-10 -cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, C 1-6 -alkyl, C 1-6 -alkoxy,
  • R 2 is selected from the group consisting of where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C 1-6 -alkyl, C 1-6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl, and C 3-10 -CyClOaIKyI;
  • R 2 is selected from the group consisting of
  • each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, Ci -6 -alkoxy, C 2- 6-alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl, and C 3-10 -cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 -heterocyclyl and C 3- i 0 -cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, Ci -6 -alkyl, C 1-6 -alkoxy, C 2-6
  • R 2 is selected from the group consisting of
  • each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl, and C 3-10 -cycloalkyl;
  • R 2 is selected from the group consisting of
  • the invention is related to a compound wherein R 2 is selected from the group consisting of
  • the invention is related to a compound wherein R 2 is selected from the group consisting of
  • the invention is related to a compound wherein R 1 is selected from the group consisting of
  • the invention is related to a compound wherein R 1 is selected from the group consisting of
  • the invention is related to a compound wherein R 1 is selected from the group consisting of
  • the invention is related to a compound wherein R 1 is selected from the group-consisting of
  • R 1 is selected from the group consisting of
  • each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C 1-6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3 ⁇ -heterocyclyl, and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C 1-6 -alkyI, Ci -6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C ⁇ s-heterocyclyl and Cs-io-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, C 1-6 -alkyl, C 1-6 -aikoxy, C 2
  • each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, Ci -6 -alkyl, C 1-6 -alkoxy, C 2-6 -alkenyl, aryl, heteroaryl, C 3-8 - heterocyclyl, and C 3- io-cycloalkyl;
  • R 1 is selected from the group consisting of
  • each Rx is independently selected from halogen, perhalomethyl, perhalomethoxy, C 1-
  • R 4 is selected from fluor, chlor, methyl, perhalomethyl or perhalomethoxy.
  • the invention is concerned with compounds, having one free -
  • the invention is concerned with compounds having one free amino group, or one monosubstituted amino group or one disubstituted amino group. In another embodiment the invention is concerned with compounds having one substituted or unsubstituted pyridine ring.
  • the invention is concerned with compounds having one substituted or unsubstituted imidazole ring. In another embodiment the invention is concerned with compounds wherein the molar weight of said compound is less than 650 g/mole.
  • the property cLog P of a compound which has no ionisable group is calculated using Sybyl 6.6 from Tripos Corporation, version 4.0 (provided by Biobyte Corp., Claremont CA, USA).
  • the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 6.0.
  • the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 5.0.
  • the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 4.0.
  • the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 2.0 to 4.0.
  • Tripos Corporation i.e. the number of H-bond donors, the number of H-bond acceptors, the number of rotatable bonds.
  • the polar surface area (PSA) is calculated using the SAVoI program Based on SAVoI 3.7 using Allinger vdw radii.
  • Polar atoms are oxygens, nitrogens, plus hydrogens attached to O and N developed by R. S. Pearlman, J. M. Skell and F. Deanda, Laboratory for Molecular Graphics and Theoretical Modeling, College of Pharmacy, University of Texas, Austin, TX 78712, U.S.A.
  • the invention is concerned with compounds wherein the ACD LogD is in the range from 0.8 to 3.0. In another embodiment the invention is concerned with compounds wherein the number of H-bond donors is 0, 1 , 2 or 3.
  • the invention is concerned with compounds wherein the number of H-bond donors is 0, 1 , or 2.
  • the invention is concerned with compounds wherein the number of H-bond acceptors is in the range from 4 to 9. In another embodiment the invention is concerned with compounds wherein the number of H-bond acceptors is in the range from 6 to 8.
  • the invention is concerned with compounds wherein the number of rotatable bonds of said compound is in the range from 4 to 14. In another embodiment the invention is concerned with compounds wherein the number of rotatable bonds of said compound is in the range from 8 to 12. In another embodiment the invention is concerned with compounds wherein the polar surface area (PSA) is in the range from 50 A 2 to120 A 2 .
  • PSA polar surface area
  • the invention is concerned with compounds wherein the polar surface area (PSA) is in the range from 60 A 2 to100 A 2 .
  • PSA polar surface area
  • Methyl-phenyl-carbamic acid 5-(4-dimethylaminomethyl-benzoylamino)-pyridin-2-yl es- ter.Methyl-phenyl-carbamic acid 5-(4-diethylaminomethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoyIamino)-pyridin-2-yl ester,
  • Methyl-phenyl-carbamic acid 5-[(piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester
  • Methyl-phenyl-carbamic acid 5-[(4-methyl-piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester
  • Methyl-p-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/-[1 ,3']bipyridinyl-6'- yl ester,
  • Methyl-m-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/-[1,3']bipyridinyl-6'- yl ester,
  • Methyl-(3-trifluorornethyl-phenyl)-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2H-[1 ,3']bipyridinyl-6'-yl ester, (3-Bromo-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1.S'Jbipyridinyl- ⁇ '-yl ester,
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the invention is concerned with a pharmaceutical composition in unit dosage form, comprising from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of said compound according to the invention or pharmaceutically acceptable salt thereof.
  • the invention is concerned with a pharmaceutical composition for use as a medicament for inhibiting the lipolytic activity of hormone-sensitive lipase against triacyl- glycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters, said composition comprising a compound according to the invention or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the invention is concerned with a pharmaceutical composition which is for oral administration. In another embodiment the invention is concerned with a pharmaceutical composition which is for nasal, transdermal, pulmonal, or parenteral administration.
  • the present invention relates to use of a compound according to the invent- tion for the preparation of a pharmaceutical composition.
  • the invention is concerned with use of a compound according to the invention for inhibition of hormone sensitive lipase.
  • the invention is concerned with use of a compound according to the invention for preparation of a pharmaceutical composition for inhibition of the lipolytic activity of hormone-sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters.
  • the invention is concerned with use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment or prevention of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and/or modulate intracellular triacylglycerol and cholesterol ester stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA; and/or increase insulin sensitivity in adipose tissue, skeletal muscle, liver or pancreatic ⁇ cells; and/or modulate insulin secretion from pancreatic ⁇ cells.
  • fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA
  • the invention is concerned with the above use wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 , diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism and any combination thereof.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of dyslipidemia.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of hyperlipidemia.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of hyperglycemia.
  • the invention is concerned with the use of a compound according to the invention for lowering HbA 10 .
  • the invention is concerned with the preparation of a pharmaceutical composition for the treatment and/or prevention of diabetes type 2.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention impaired glucose tolerance.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of metabolic syndrome X.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of atheroschlerosis.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for delaying or prevention of the progression from impaired glucose tolerance to diabetes type 2.
  • the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for delaying or prevention of the progression from non-insulin requiring diabetes type 2 to insulin requiring diabetes type 2.
  • the invention is concerned with the use according to above indica- tionns wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is used.
  • the invention is concerned with the use according to above indications, wherein metformin is also used.
  • the present invention is related to a method of treating a disorder of a patient where modulation of the activity of hormone-sensitive lipase is desired, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof.
  • the invention is concerned with a method of treating a disorder of a patient where lowering of the activity of hormone-sensitive lipase is desired, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to the invention or a pharmaceutically acceptable salt thereof.
  • the invention is concerned with the above methods wherein said administration is carried out by the oral, nasal, transdermal, pulmonal, or parenteral route.
  • the invention is concerned with the above methods wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 , diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atherosclerosis, hypertension, abnormalities of lipoprotein metabolism and any combination thereof.
  • the invention is concerned with the above methods wherein the therapeutically effective amount of the compound is from about 0.05 to about 2000 mg, pref- erably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of said compound per day.
  • the invention is concerned with the above methods wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is administered to the patient.
  • the invention is concerned with above methods wherein metformin is also administered to the patient.
  • the present invention is related to a process P 1 for the preparation of a compound of the invention or its pharmaceutically acceptable salt, which comprises reacting the appropriate alcohol with the appropriate carbamoylating reagent in a solvent according to the reaction scheme P 1 and isolating the disubstituted carbamate product.
  • said solvent is selected from the group consisting of tetrahydrofurane, dimethylformamide and N-methylpyrolidone.
  • said base is selected from the group consisting of triethylamine, N,N-diisopropyl-N-ethylamine and DABCO.
  • the present invention relates to a process P 2 for the preparation of a compound of the invention, said process comprising the treatment of the appropriate amine with the appropriate acylating reagent in a solvent and in the presence of a base according to the reaction scheme P 2
  • Lv is CI.
  • said solvent is selected from the group consisting of diethyl ether, tetrahydrofuran and dichloromethane.
  • said base is selected from the group consisting of trimethylamine, triethylamine, ethyl-diisopropyl-amine and 1 ,4-diazabicyclo[2.2.2]octane.
  • said base is present as a functionality in one or both of the substituents R 3 and R 4 , thus forming a salt with the acid H-Lv.
  • the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
  • Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, parnoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaph- thoates, glycero
  • compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
  • metal salts include lithium, sodium, potassium, magnesium, zinc, calcium salts and the like.
  • amines and organic amines include ammonium, methylamine, di- methylamine, trimethylamine, ethylamine, diethylamine, propylamine, butylamine, tetrame- thylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylenediamine, N-benzylphenylethylamine, N-methyl-D-glucamine, guanidine and the like.
  • cationic amino acids include lysine, arginine, histidine and the like.
  • the pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used.
  • a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like
  • solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc.
  • Organic bases like lysine, arginine, diethanolamine, choline
  • acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
  • acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic
  • stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods.
  • Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, (R)- or (S)-phenylethylamine, cinchona alkaloids and their derivatives and the like.
  • the compound of formula I may be converted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydrolysing the pure diastereomeric amide.
  • polymorphs of compound of general formula I forming part of this invention may be prepared by crystallization of compound of formula I under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calo- rimetry, powder X-ray diffraction or such other techniques.
  • the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
  • prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula I.
  • Conventional procedures for the selection and preparation of suitable prodrug de- rivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the invention also encompasses active metabolites of the present compounds.
  • the invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the formula I or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.
  • the invention relates to the use of compounds of the general formula I or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically ac- ceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of disorders where a decreased level of plasma FFA is desirable, such as the conditions mentioned above.
  • the present invention relates to a method of treating and/or preventing type 2 diabetes, insulin resistance, metabolic syndrome X, impaired glucose tolerance, dyslipidemia and abnormalities of lipoprotein metabolism.
  • the present invention relates to the use of one or more compounds of the general formula I, or pharmaceutically acceptable salts thereof, for the preparation of a pharmaceutical composition for the treatment and/or prevention of type 2 diabetes, insulin resistance, metabolic syndrome X, impaired glucose tolerance, dyslipidemia and abnormalities of lipoprotein metabolism.
  • the present compounds are useful for the delaying or prevention of the progression from impaired glucose tolerance to type 2 diabetes.
  • the present compounds are useful for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes.
  • the present compounds reduce triglyceride levels and are accordingly useful for the treatment and/or prevention of ailments and disorders such as diabetes and/or obesity.
  • the compounds of general formula I are useful for the treatment of hy- perglycemia, elevated HbA 10 level, hyperinsulinemia, type 1.5 diabetes, latent autoimmune diabetes in adults, maturity onset diabetes, beta-cell apoptosis, hemochromatosis induced diabetes, impaired glucose tolerance, impaired fasting glucose, metabolic syndrome X, insulin resistance, impaired lipid tolerance, cystic fibrosis related diabetes, polycystic ovarian syndrome, and gestational diabetes.
  • the compounds of general formula I are useful for the treatment of obesity, dyslipidemia, diabetic dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, hypertension, essential hypertension, acute hypertensive emergency, arteriosclerosis, atherosclerosis, restenosis, intermittent claudication (atherosclerosis oblitterens), cardiovascular disease, cardiomyopathy, cardiac hypertrophy, left ventricular hypertrophy, coronary artery disease, early coronary artery disease, heart insufficiency, exercise tolerance, chronic heart failure, mild chronic heart failure, arrhythmia, cardiac dysrythmia, syncopy, heart attack, myocardial infarction, Q-wave myocardial infarction, stroke, acute coronary syndrome, angina pectoris, unstable angina, cardiac bypass re- occlusion, diastolic dysfunction, systolic dysfunction, non-Q-wave cardiac necrosis, catabolic changes after surgery, acute pancreatitis, and
  • the compounds of general formula I may be useful for the treatment of diabetic retinopathy, background retinopathy, preproliferative retinopathy, prolif- erative retinopathy, macular edema, cataracts, nephropathy, nephrotic syndrome, diabetic nephropathy, microalbuminuria, macroalbuminuria, neuropathy, diabetic neuropathy, distal symmetrical sensorimotor polyneuropathy, and diabetic autonomic neuropathy.
  • the compounds of general formula I are useful for increasing the number of beta-cells in a patient, increasing the size of beta-cells in a patient or stimulating beta-cell proliferation, modulating beta-cell function and insulin secretion in a patient in need thereof, which method comprises administration of an effective amount of a compound of formula I to a patient in need thereof.
  • the compounds of the invention are also believed to be useful for reducing body weight in a patient in need thereof.
  • the compounds of the invention are also believed to be useful for weight neutral treatment of above mentioned diseases.
  • the compounds of the invention are also believed to be useful for redistributing fat in a pa- tient in need thereof.
  • the compounds of the invention are also believed to be useful for redistributing central fat in a patient in need thereof.
  • the compounds of the invention are also believed to be useful for reducing or preventing central obesity.
  • the compounds of the invention are also believed to be useful for reducing postprandial serum lipid excursions.
  • the compounds of the invention are also believed to be useful for the treatment of fatty acid oxidation disorders such as MCAD.
  • the compounds of general formula I are believed to be useful for the treatment of a disease, condition or disorder wherein cholesterol is a precursor.
  • diseases, conditions or disorders may relate to testosterone, e.g. male contraception, excessive testosterone levels, PCOS and prostate cancer. They may also relate to Cortisol or cortico- tropin, e.g. Cushing disease.
  • the compounds of the invention are also believed to be useful for the treatment of cancer.
  • the compounds of the general formula I may be useful for the treatment of insulinoma (pancreatic islet cell tumors), e.g. malignant insulinomas and multiple insulinomas, adipose cell carcinomas, e.g. lipocarconoma.
  • insulinoma pancreatic islet cell tumors
  • adipose cell carcinomas e.g. lipocarconoma
  • the compounds of the invention are also believed to be useful for the treatment of phaechromocytoma and other diseases with increased catecholamine incretion.
  • the compounds of the invention are also believed to be useful for the treatment of prostate cancer, e.g. adenocarcinoma.
  • the compounds of general formula I may be useful for the treatment of hepatic steatosis.
  • the compounds of general formula I may be useful for the treatment of cirrhosis. In still another aspect, the compounds of general formula I may be useful for the treatment of AIDS or an AIDS related diseases, condition or disorders
  • the compounds of general formula I may be useful for the treatment of lipodystrophy
  • the compounds of general formula I may be useful for the treatment of lactic acidosis.
  • the compounds of the present invention are expected to be useful for the treatment of CNS diseases, conditions or disorders.
  • the compound of the present invention may be used for the treatment of Parkinsons disease, Alzheimers disease, ADHD (Attention Deficit Hyperactivity Disorder), feeding disorders such as bulimia and anorexia, depression, anxiety, cognitive memory disorders, age related cognitive decline, mild cognitive impairment and schizophrenia.
  • the compounds of the present invention may be useful for the treatment of inflammatory disorders, e.g. rheumatoid arthritis, psoriasis, systemic inflammatory response syndrome, sepsis and the like.
  • the present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment and/or prevention of complications re- suiting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment and/or prevention of complications re- suiting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • Such agents may be selected from the group consisting of CART (cocaine am- phetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melano- cortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, se- rotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone
  • the antiobesity agent is leptin.
  • the antiobesity agent is dexamphetamine or amphetamine.
  • the antiobesity agent is fenfluramine or dexfenfluramine.
  • the antiobesity agent is sibutramine. In a further embodiment the antiobesity agent is orlistat.
  • the antiobesity agent is mazindol or phentermine.
  • Suitable antidiabetics comprise insulin, exendin-4, GLP-1 (glucagon like peptide-1) and derivatives thereof such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents.
  • the orally active hypoglycaemic agents preferably comprise sulphonylureas, bigua- nides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase- IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenosis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potas- sium channel of the ⁇ -
  • the present compounds are administered in combination with insulin.
  • the present compounds are administered in combination with a sulphonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
  • a sulphonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
  • the present compounds are administered in combination with a biguanide eg. metformin.
  • the present compounds are administered in combination with a meglitinide eg. repaglinide or senaglinide.
  • the present compounds are administered in combination with an ⁇ -glucosidase inhibitor eg. miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor eg. miglitol or acarbose.
  • the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • the present compounds may be administered in combination with nateglinide.
  • the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofi- brate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofi- brate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • the present compounds are administered in combination with more than one of the above-mentioned compounds eg. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
  • the present compounds may be administered in combination with one or more antihypertensive agents.
  • antihypertensive agents are ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin con- verting enzyme) inhibitors such as benazepril, captopril, alatriopril, enalapril, fosinopril, lisi- nopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19 th Edition,
  • the present invention also relates to processes according to reaction schemes P 1 and P 2 for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
  • the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
  • the pharmaceutical compositions according to the invention may be formulated with pharmaceu- tically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacol 9 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
  • the compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route be- ing preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
  • compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropri- ate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well-known in the art.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
  • Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.
  • Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.
  • the therapeutic dose of the compound will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
  • the formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art.
  • the composition in unit dosage form comprises from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg of the compound of formula I pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is for oral, nasal, transdermal, pulmonal, or parenteral administration.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having the utility of a free base.
  • a compound of the invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the compound with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids. Representative examples are mentioned above.
  • Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion.
  • solutions of the present compounds in sterile aqueous solution aqueous propylene glycol or sesame or peanut oil may be employed.
  • aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
  • compositions formed by combining the compounds of the invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • the formulations may con- veniently be presented in unit dosage form by methods known in the art of pharmacy.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
  • the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emul- sion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • the compounds of the invention may be administered to a patient which is a mammal, especially a human in need thereof. Such mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife.
  • the present compounds may be administered in combination with further pharmacologically active substances e.g. an antidiabetic or other pharmacologically active material, including other compounds for the treatment and/or prevention of insulin resistance and diseases, wherein insulin resistance is the pathophysiological mechanism.
  • the compounds according to the invention may be administered in combination with antiobesity agents or appetite regulating agents.
  • Step A Thionyl chloride (100 mL) was added to a stirred solution of (6-methoxy-pyridin-3- yl)-methanol (31.0 g, 223 mmol) in chloroform (300 mL). After refluxing for 2 hours, the solvent and excess thionyl chloride were removed by evaporation in vacuo. The residue was stripped with toluene, dissolved in dichloromethane (400 mL) and extracted with a saturated aqueous sodium bicarbonate solution (200 mL). The organic layer was dried over sodium sulphate, filtered and evaporated in vacuo, yielding a yellow oil.
  • Step D During 5 minutes HCI-gas was bubbled into a solution of 1-[2-(6-methoxy-pyridin-3- yl)-ethyl]-4,4-dimethyl-piperidine-2,6-dione (1.15 g, 4.18 mmol) in tetrahydrofuran (25 mL). Ether (200 mL) was added and the solvent was evaporated in vacuo. The residue was heated for 5 minutes at 180 0 C. After cooling to room temperature the solid was dissolved in dichloromethane (10 mL).
  • Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (1.22 g, 5.00 mmol) was added in portions to a stirred solution of di-2-pyridyl thionocarbonate (1.16 g, 5.00 mmol) in 1 ,2-dichIoropropane (15 mL).
  • alpha- aminoisobutyric acid methyl ester hydrochloride (0.77 g, 5.00 mmol
  • triethylamine 0.7 mL
  • DL-alpha-amino-n-butyric acid methyl ester hydrochloride (2.00 mmol, 307 mg) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.00 mmol) in 1,2-dichloropropane (5 mL). A small amount of methanol was added to get a clear solution. Triethylamine (0.28 mL, 2.00 mmol) was added and the solution was stirred overnight at room temperature. Dichloromethane was added and the reaction mixture was extracted twice with water, dried over sodium sulphate, filtered and evaporated in vacuo.
  • O-M3utyl-D-serine acid methyl ester hydrochloride (2.00 mmol, 307 mg) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.00 mmol) in dichloromethane (10 ml_). Triethylamine (0.28 mL, 2.00 mmol) was added and the solution was stirred for 7 days at room temperature. Part of the solvent was removed by evaporation in vacuo.
  • Phosgene (5 mL, 20% in toluene) was added to a stirred suspension of 6'-hydroxy- 4,4-dimethyl-4,5-dihydro-3/-/-[1 ,3']bipyridinyl-2,6-dione (0.47 g, 2.00 mmol) and triethylamine (0.29 mL, 2.00 mmol) in dichloromethane (10 mL). After stirring for 0.75 h at room temperature, the solvent and excess phosgene were evaporated under reduced pressure, yielding a white solid.
  • Morpholine (0.144 mL, 1.65 mmol) was added to a stirred suspension of methyl- phenyl-carbamic acid 5-(4-formyl-benzoylamino)-pyridin-2-yl ester (0.56 g, 1.5 mmol) in methanol (15 mL). The solution was warmed carefully to get the starting material into solution. After stirring for 0.5 hours at room temperature sodium cyanoborohydride (104 mg, 1.65 mmol) was added and stirring was continued at room temperature overnight. The solvent was evaporated and the residue purified by flash column chromatography (SiO 2 ), yielding the title compound (38 mg, 6% yield).
  • Example 46 Using the procedure as described in Example 46 and starting from 4,4- dimethylpiperidine hydrochloride (0.22 g, 1.50 mmol), ⁇ /-ethyldiisopropylamine (0.52 ml_, 3.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) and stirring for 3 days yielded the title compound (341 mg, 72% yield) as a white solid.
  • Example 46 Using the procedure as described in Example 46 and starting from 4-ketopiperidine hydrate hydrochloride (154 mg, 1.00 mmol), /V-ethyldiisopropylamine (259 mg, 2.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) and stirring for 2 days yielded the title compound (358 mg, 78% yield).
  • Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.73 g, 3.00 mmol) was added to a solution of di-2-pyridyl thionocarbonate (0.70 g, 3.00 mmol) in dichloromethane (15 mL). After stirring for 2 hours 2-amino-2-methyl-1-propanol (0.27 g, 3.00 mmol), dissolved in a small amount of dichloromethane, was added in one portion. Stirring was continued overnight at room temperature. The product was purified by flash column chromatography (SiO 2 , gradient of 80-100% ethyl acetate in heptane). Crystallisation from ethyl ace- tate/heptane yielded the title compound (907 mg, 81 % yield) as a white solid.
  • Methyl-phenyl-carbamic acid 5-amino-pyridin-2 ⁇ yl (243 mg, 1.00 mmol) was added to a solution of di-2-pyridyl thionocarbonate (232 mg, 1.00 mmol) in dichloromethane (5 mL).
  • Step A A solution of 4-aminophenethylalcohol (2.03 g, 14.8 mmol) in ethyl formate (15 mL) was heated at reflux overnight. After cooling to room temperature heptane was added to the reaction mixture. The solvent was decanted from the oil and the last traces of solvent were removed in vacuo. Dichloromethane was added to the residue and the precipitate was isolated by suction, yielding ⁇ /-[4-(2-hydroxyethyl)-phenyl]-formamide (1.95 g, 80% yield), which was used without further purification in the next step
  • Step B Under a nitrogen atmosphere, a solution of ⁇ /-[4-(2-hydroxyethyl)-phenyl]-formamide
  • Compounds of formula I may be evaluated in vitro for their efficacy and potency to inhibit HSL, and such evaluation may be performed as described below.
  • HSL Hormone-sensitive lipase
  • the Hormone-sensitive lipase was provided by Dr. Cecilia Holm, from Lund University Sweden or produced and purified by Novo Nordisk (NN) using the reagents and protocols used by Dr. Holm.
  • the substrates used are: 3 H-Iabeled triolein (TO) from Amersham, Buckinghamshire, U.K. cat No. TRA191 ; 5-20 Ci/mmol dissolved in toluene, triolein (Sigma, Cat. No.
  • PC phosphatidyl choline
  • Pl phosphatidyl inositol
  • a lipid emulsion with fluorochrome-labeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12 ⁇ g/mL initial concentration corresponding to 600ng/mL final concentration). BSA is added as product acceptor.
  • the transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluo- rescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm.
  • Compound and HSL (20 ⁇ L compound, 10 ⁇ l_ enzyme and 70 ⁇ L PED-BSA buffer) is pre-incubated for 30min at 25 0 C before addition of substrate (100 ⁇ l_). Amount of formed product is measured after 120min incubation at 37 0 C.
  • Results are given as percent activity relative to a non-inhibited sample (no compound).
  • 3190.2 Assay for determination of IC 50 value for the inhibition of hormone sensitive lipase by compound. Standard concentrations of compound are 100//M and 5-fold dilutions (initial concentration corresponding to 10//M final concentration and 5-fold).
  • a lipid emulsion with fluorochrome-iabeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12 ⁇ g/mL initial concentration corresponding to 600ng/mL final concentration).
  • BSA is added as product acceptor.
  • the transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluorescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm.
  • Compound and HSL (20 ⁇ L compound, 10 ⁇ L enzyme and 70 ⁇ L PED-BSA buffer) is pre-incubated for 30min at 25 0 C before addition of substrate (1 OO ⁇ L). Amount of formed product is measured after 120min incubation at 37 0 C.
  • Results are given as IC 50 values after 4PL fit of obtained activity data.

Abstract

Novel substituted pyridinyl carbamates of general formula (I):, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial.

Description

PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS
FIELD OF THE INVENTION
The present invention relates to novel substituted pyridinyl carbamates, to pharma- ceutical compositions comprising these compounds, to the use of these compounds as pharmaceutical compositions, and to methods of treatment employing these compounds and compositions. The present compounds show inhibition of hormone sensitive lipase. As a result, the compounds are useful for the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase.
BACKGROUND OF THE INVENTION
The overall energy homeostasis of a mammalian system requires a high degree of regulation to ensure the availability of the appropriate substrate at the appropriate time. Plasma glucose levels rise during the post-prandial state, to return to pre-prandial levels within 2-3 hours. During these 2-3 hours, insulin promotes glucose uptake by skeletal muscle and adipose tissue and decreases the release of free fatty acids (FFA) from adipocytes, to ensure that the two substrates do not compete with each other. When plasma glucose levels fall, an elevation in plasma FFA is necessary to switch from glucose to fat utilization by the various tissues. In individuals with insulin resistance, FFA levels do not fall in response to insulin, as they do in normal individuals, preventing the normal utilization of glucose by skeletal muscle, adipose and liver. Furthermore, there is a negative correlation between insulin sensitivity and plasma FFA levels.
Hormone-sensitive lipase (HSL) is an enzyme, expressed in adipose tissue, macro- phages, muscle, adrenal, testis and islets (Kraemer and Shen, J. Lipid Res. 2002, 43, 1585- 1594). In the adipocytes HSL catalyses the conversion of triglycerides to glycerol and fatty acids. It is through the regulation of this enzyme that the levels of circulating FFA are modulated. Insulin leads to the inactivation of HSL with a subsequent fall in plasma FFA levels during the post-prandial state, followed by the activation of the enzyme when the insulin concen- tration falls and catecholamines rise during the post-absorptive period. The activation of HSL leads to an increase in plasma FFA, as they become the main source of energy during fasting. The activation-inactivation of HSL is primarily mediated through the cAMP-protein kinase A and AMP-dependent kinase pathways. There are compounds like nicotinic acid and its derivatives, that decrease the activation of HSL via these pathways and cause a decrease in lipolysis that leads to a reduction in the FFA levels. These drugs have a beneficial effect in the utilization of glucose and in the normalization of the excess triglyceride synthesis seen in patients with elevated FFA. However, since these pathways are used by other processes in the body, these drugs have severe side effects.
Carbamates similar to the compounds of the present invention have previously been prepared. Ross Kelly et al. (Org. Lett. 24(1), 2001 , 3895-3898) disclose the following com- pound and its use in a chemically powered molecular motor :
ks^J ' K^ o
Several publications disclose the preparation and use of HSL inhibitors (WO 01/87843, WO 01/17981, WO 01/66531, WO 01/83497, and WO 01/26664). However, the structures of these compounds are very different from that of the present compounds. Thus, none of the HSL inhibitors disclosed in these publications contain pyridinyl and carbamate substructures as in the compounds of the present invention.
We have found potent pyridinyl carbamate compounds that specifically inhibit the lipolytic activity of HSL and which may be expected to decrease plasma FFA levels. These compounds can be used to treat disorders where a decreased level of plasma FFA is de- sired, such as insulin resistance, syndrome X, dyslipidemia, abnormalities of lipoprotein metabolism.
One object of the present invention is to provide compounds and pharmaceutical compositions that inhibit the lipolytic activity of HSL. A further object is to provide compounds which have good pharmaceutical properties such as solubility, bioavailability, specificity etc.
DEFINITIONS
The following is a detailed definition of the terms used to describe the compounds of the invention.
The term "halogen" in the present context designates an atom selected from the group consisting of F, Cl, Br and I.
The term "C1-6-alkyI" in the present context designates a saturated, branched or straight hydrocarbon group having from 1 to 6 carbon atoms. Representative examples in- elude, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl, isopentyl, neopentyl, terf-pentyl, n-hexyl, isohexyl and the like.
The term "C2-6-alkyI" in the present context designates a saturated, branched or straight hydrocarbon group having from 2 to 6 carbon atoms. Representative examples in- dude, but are not limited to, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, ferf-butyl, n- pentyl, isopentyl, neopentyl, ferf-pentyl, n-hexyl, isohexyl and the like.
The term "C1-6-alkoxy" in the present context designates a group -O-C-i-β-alkyl wherein d-6-alkyI is as defined above. Representative examples include, but are not limited to, meth- oxy, ethoxy, n-propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, ferf-butoxy, n-pentoxy, isopentoxy, neopentoxy, terf-pentoxy, n-hexoxy, isohexoxy and the like.
The term "C2-6-alkenyl" as used herein, represent an olefinically unsaturated branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2- propenyl, allyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like. The term "C3-10-cycloalkyl" as used herein represents a saturated mono-, bi-, tri- or spirocarbocyclic group having from 3 to 10 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclode- cyl, bicyclo[3.2.1]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl and the like. The term "Ca^-heterocyclyl" as used herein represents a saturated 3 to 8 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. Representative examples are pyrrolidyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, azirid- inyl, tetrahydrofuranyl and the like.
The term "aryl" as used herein represents a carbocyclic aromatic ring system being either monocyclic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenylenyl and the like. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic aromatic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1 ,2,3,4-tetrahydronaphthyl, 1 ,4-dihydronaphthyl and the like.
The term "heteroaryl" as used herein represents a heterocyclic aromatic ring system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1 ,2,3-triazoIyl, 1 ,2,4- triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1 ,2,3-triazinyl, 1 ,2,4-triazinyl, 1 ,3,5- triazinyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,3- thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, 1 ,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indo- IyI, isoindolyl, benzofuranyl, benzothiophenyl (thianaphthenyl), indazolyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, di- azepinyl, acridinyl and the like. Heteroaryl is also intended to include the partially hydrogen- ated derivatives of the heterocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, 3,4-dihydroisoquinolinyl, pyrrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like.
The term "perhalomethyl" as used herein designates a methyl moiety substituted with three halogen atoms. Non-limiting examples of perhalomethyl are CF3, CCI3, and CF2CI. The term "perhalomethoxy" as used herein designates a perhalomethyl linked via an oxygen atom, e.g. -0-CF3, -0-CCl3, and -0-CF2Cl
The term "ring system" as used herein includes aromatic as well as non-aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and they encompass moieties with zero, one or more hetereatoms selected from nitrogen, oxygen and sulphur. Non-limiting examples of such ring systems are aryl, C3^-heterocyclyl and heteroaryl. The term "heterocyclic system" as used herein includes aromatic as well as non- aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and containing in their ring structure one or more heteroatoms selected from nitrogen, oxygen and sulfur. Non- limiting examples of such heterocyclic systems are C3-8-heterocyclyl and heteroaryl.
Certain of the above defined terms may occur more than once in the structural for- mulae, and upon such occurrence each term shall be defined independently of the other.
The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent the substituents may be the same or different. The terms "disease", "condition" and "disorder" as used herein are used interchangeably to specifiy a state of a patient which is not the normal physiological state of man. The term "treatment" as used herein means the management and care of a patient having developed a disease, condition or disorder, as well as the management and care of an individual at risk of developing the disease, condition or disorder prior to the clinical onset of said disease, condition or disorder. The purpose of treatment is to combat the disease, condition or disorder, as well as to to combat the development of the disease, condition or disorder. Treatment includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the dis- ease, condition or disorder. The term "effective amount" as used herein means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment.
The term "modulate" as used herein means to influence, i.e. to modulate a parameter means to influence that parameter in a desired way. Examples are to modulate insulin secretion from beta cells and to modulate the plasma level of free fatty acids.
The term "medicament" as used herein means a pharmaceutical composition suitable for administration of the pharmaceutically active compound to a patient.
The term "pharmaceutically acceptable" as used herein means suited for normal pharmaceutical applications, i.e. giving rise to no adverse events in patients etc.
DESCRIPTION OF THE INVENTION
In one aspect the present invention relates to a compound of the general formula (I)
wherein
R1 and R2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, amide, urea, thiourea, benzamide, thioamide, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, amide, urea, thiourea, benzamide, thioamide, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, het- eroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, thioxo, halogen, amino, sulfo, d.6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-10- cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3_10-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-CyClOaIkYl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-CyClOaIkYl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C1-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not 2,2-Dimethyl-Λ/-[6-(methyl-phenyl-carbamoyIoxy)-pyridin-3-yl]-succinamic acid,3,3-Dimethyl- 4-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-ylcarbarnoyl]-butyric acid, Methyl-phenyl- carbamic acid pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 3-chloro-5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5- benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(cyclohexanecarbonyl- amino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6- tetrahydro-2H-[1,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl- propionylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2-cyclohexyl- acetylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-butyrylamino)- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(pyridine-2-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(6-chloro-pyridine-3-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 2,6-dioxo-3,4,5,6-tetrahydro-2H-[1,3I]bipyridinyl-6'-yl ester, Methyl- phenyl-carbamic acid 5-(2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-benzenesulfonylamino-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-(3,3-dimethyl-2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-[3,3-dimethyl-5-(4-methyl-piperazin-1-yl)-5-oxo-pentanoylamino]- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[3,3-dimethyl-4-(pyridin-3-ylcarbamoyl)- butyrylamino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-5-morpholin-4- yl-5-oxo-pentanoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[4-(2- dimethylamino-ethylcarbamoyO-S.S-dimethyl-butyrylaminoj-pyridin^-yl esterjN-Methyl-N- phenylcarbamic acid 5-nitro-3-trifluoromethylpyridin-2-yl ester, N-Methyl-N-phenylcarbamic acid 3-nitropy rid i n-2-yl ester, and N-Methyl-N-phenylcarbamic acid 5-nitropyridin-2-yl ester
as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In one embodiment R2 is selected from hydrogen, hydroxy, amino, halogen, Ci-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^-heterocyclyl, amide, urea and thiourea and C3-10-CyClOaIRyI, wherein each of hydroxy, amino, C1-6-aikyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, amide, urea and thiourea and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and Ca-io-cycloalkyl. In another embodiment R2 is halogen or hydrogen.
In another embodiment R4 is selected from hydrogen, halogen, C1-6-alkyl, C2-6- alkenyl, wherein each of C1-6-alkyl, C2-6-alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-β-heterocyclyl and C^o-cycloalkyl. In another embodiment R4 is selected from hydrogen, halogen and C1-6-alkyl.
In another embodiment R4 is hydrogen.
In another embodiment R4 is halogen.
In another embodiment R3 is selected from hydrogen, hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, wherein each of hydroxy, C1-6-alkyl, C2-6-alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C1-6-alkyl, C2-6- alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl.
In another embodiment R3 is selected from halogen, C1-6-alkyl, methoxy, perha- lomethyl and perhalomethoxy.
In another embodiment R3 is selected from halogen, methyl, ethyl, isopropyl, meth- oxy and perhalomethyl.
In another embodiment R3 is selected from halogen, methyl, methoxy and perhalomethyl.
In another aspect the present invention relates to a compound of the general for- mula (I) : wherein
R1 and R2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, amide, urea, thiourea, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and wherein each of hydroxy, sulfanyl, amino, amide, urea, thiourea, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6- alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3.10-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, d-6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-aIkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and Cs-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycIoalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C1-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not
2,2-Dimethyl-Λ/-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-yl]-succinamic acid,3,3-Dimethyl- 4-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-ylcarbamoyl]-butyric acid , Methyl-phenyl- carbamic acid pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 3-chloro-5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5- benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(cyclohexanecarbonyl- amino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl- propionylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2-cyclohexyl- acetylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-butyrylamino)- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(pyridine-2-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(6-chIoro-pyridine-3-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 2,6-dioxo-3 ,4,5,6-tetrahydro-2/-/-[1 ,3']bipyridinyl-6'-yl ester, Methyl- phenyl-carbamic acid 5-(2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyi-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-benzenesulfonylamino-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-(3,3-dimethyl-2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-[3,3-dimethyl-5-(4-methyl-piperazin-1 -yl)-5-oxo-pentanoylamino]- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[3,3-dimethyl-4-(pyridin-3-ylcarbamoyl)- butyrylamino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-5-morpholin-4- yI-5-oxo-pentanoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[4-(2- dimethylamino-ethylcarbamoyl)-3,3-dimethyI-butyrylamino]-pyridin-2-yl ester; as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
> In one embodiment R2 is selected from hydrogen, hydroxy, amino, halogen, C1-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, amide, urea and thiourea and C3-10-cycloalkyl, wherein each of hydroxy, amino, Ci-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, amide, urea and thiourea and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-β-heterocyclyl, and Ca-io-cycloalkyl.
In another embodiment R2 is halogen or hydrogen.
In another embodiment R4 is selected from hydrogen, halogen, C1-6-alkyl, C2-6- alkenyl, wherein each of C1-6-alkyl, C2-6-alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, aryl, het- eroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl.
In another embodiment R4 is selected from hydrogen, halogen and C1-6-alkyl.
In another embodiment R4 is hydrogen. ; In another embodiment R4 is halogen.
In another embodiment R3 is selected from hydrogen, halogen, C1-6-alkyl, C2-6- alkenyl, wherein each of , d-6-alkyl, C2-6-alkenyI is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, aryl, het- eroaryl, Cs-s-heterocyclyl and In another embodiment R3 is selected from halogen, d-β-alkyl, perhalomethyl and perhalomethoxy.
In yet another embodiment R3 is selected from halogen, methyl, ethyl, isopropyl and perhalomethyl.
In yet another embodiment R3 is selected from halogen, methyl or perhalomethyl.
In another aspect the present invention relates to a compound of the general formula (I) :
wherein R1 and R2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10- cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-8-heterocyclyl and C^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, Ci-e-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and Cs-io-cycloalkyl; R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents inde- pendently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C^-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyI, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, d-β-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not
2,2-Dimethyl-Λ/-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-yl]-succinamic acid,3,3-Dimethyl- 4-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-ylcarbamoyl]-butyric acid, Methyl-phenyl- carbamic acid pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 3-chloro-5-trifluoromethyl-pyridin-2-yI ester, Methyl-phenyl-carbamic acid 5- benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(cycIohexanecarbonyl- amino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl- propionylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2-cyclohexyl- acetylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-butyrylamino)- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(pyridine-2-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(6-chloro-pyridine-3-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 2,6-dioxo-3,4,5,6-tetrahydro-2H-[1.STbipyridinyl-β'-yl ester, Methyl- phenyl-carbamic acid 5-(2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-benzenesulfonylamino-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-(3,3-dimethyl-2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-[3,3-dimethyl-5-(4-methyl-piperazin-1 -yl)-5-oxo-pentanoylamino]- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[3,3-dimethyl-4-(pyridin-3-ylcarbamoyl)- butyrylamino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-5-morpholin-4- yl-5-oxo-pentanoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[4-(2- dimethylamino-ethylcarbamoyl)-3,3-dimethyl-butyrylamino]-pyridin-2-yl ester; as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In another aspect the present invention is related to a compound of the general formula (I)
wherein R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, d-β-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, Ci-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents inde- pendently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3.8-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, Ci-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In another aspect the present invention is related to a compound of the general formula (I) :
CH, R" wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, Ci_6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, C1-6-aIkyl, C2-6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-i0-cycIoalkyl is optionally substituted with one or more substituents inde- pendently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-β-heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyciyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C^-alky!, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In another aspect the present invention is related to a compound of the general formula (I) :
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3.10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-aIkoxy, C2-6-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C^s-heterocyclyl, and Cs-io-cycloalkyl;
R3, and R4 are hydrogen
with the proviso that said compound is not Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In another aspect the present invention is related to a compound of the general formula (I) :
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C^o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl;
R3, and R4 are hydrogen
with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In another aspect the present invention is related to a compound of the general formula (I) :
wherein R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, amino, halogen, C1-6-alkyl, C1-6- alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Ca-io-cycloalkyl, wherein each of hydroxy, d-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10- cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyI, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and Ca.-m-cycloalkyl,
R3 and R4 are hydrogen
with the proviso that said compound is not Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In another aspect the present invention is related to a compound of the general formula (I)
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, amino, halogen, C1-6-alkyl, C1-6- alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-β-heterocyclyl and CMo-cycloalkyl, wherein each of hydroxy, amino, C1-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3- 10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^-heterocyclyl, and C3-10-cycloalkyl,
R3 and R4 are hydrogen
with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
In one embodiment the invention is related to a compound wherein R2 is selected from from hydrogen, hydroxy, amino, halogen, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, C1-6-alkyl, C1-6-alkoxy, C2-6- alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10- cycloalkyl.
In one embodiment the invention is related to a compound wherein R3 is selected from fluor, chlor, methyl, perhalomethyl or perhalomethoxy.
In one embodiment the invention is related to a compound wherein R2 is hydrogen. In another embodiment the invention is related to a compound wherein R2 is selected from the group consisting of
In another embodiment R2 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, d-e-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10-CyClOaIRyI, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl;
In yet another embodiment R2 is selected from the group consisting of where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-CyClOaIKyI;
In another embodiment R2 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl;
In another embodiment R2 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl; In another embodiment R2 is selected from the group consisting of
In one embodiment the invention is related to a compound wherein R2 is selected from the group consisting of
In one embodiment the invention is related to a compound wherein R2 is selected from the group consisting of
In one embodiment the invention is related to a compound wherein R1 is selected from the group consisting of
In one embodiment the invention is related to a compound wherein R1 is selected from the group consisting of
In one embodiment the invention is related to a compound wherein R1 is selected from the group consisting of
In another embodiment the invention is related to a compound wherein R1 is selected from the group-consisting of
In another embodiment of the invention is related to a compound wherein R1 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyI, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^s-heterocyclyl and Cs-io-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, C1-6-alkyl, C1-6-aikoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl; In another embodiment of the invention is related to a compound wherein R1 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-io-cycloalkyl;
In another embodiment of the invention is related to a compound wherein R1 is selected from the group consisting of
where each Rx is independently selected from halogen, perhalomethyl, perhalomethoxy, C1-
6-alkyl, heteroaryl, Ca-a-heterocyclyl, and C3-10-cycIoaIkyI;
In another embodiment of the invention is related to a compound wherein R3 is hydrogen.
In another embodiment of the invention is related to a compound wherein R4 is hydrogen.
In another embodiment of the invention is related to a compound wherein R4 is selected from fluor, chlor, methyl, perhalomethyl or perhalomethoxy.
In another embodiment the invention is concerned with compounds, having one free -
COOH group.
In another embodiment the invention is concerned with compounds having one free amino group, or one monosubstituted amino group or one disubstituted amino group. In another embodiment the invention is concerned with compounds having one substituted or unsubstituted pyridine ring.
In another embodiment the invention is concerned with compounds having one substituted or unsubstituted imidazole ring. In another embodiment the invention is concerned with compounds wherein the molar weight of said compound is less than 650 g/mole.
The property cLog P of a compound which has no ionisable group is calculated using Sybyl 6.6 from Tripos Corporation, version 4.0 (provided by Biobyte Corp., Claremont CA, USA). In another embodiment the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 6.0. In another embodiment the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 5.0. In another embodiment the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 4.0. In another embodiment the invention is concerned with compounds wherein the compound contains no ionisable group and wherein cLog P is in the range from 2.0 to 4.0.
A number of other properties of the compounds are calculated using Sybyl 6.6. from
Tripos Corporation, i.e. the number of H-bond donors, the number of H-bond acceptors, the number of rotatable bonds. The polar surface area (PSA) is calculated using the SAVoI program Based on SAVoI 3.7 using Allinger vdw radii. Polar atoms are oxygens, nitrogens, plus hydrogens attached to O and N developed by R. S. Pearlman, J. M. Skell and F. Deanda, Laboratory for Molecular Graphics and Theoretical Modeling, College of Pharmacy, University of Texas, Austin, TX 78712, U.S.A.
In another embodiment the invention is concerned with compounds wherein the ACD LogD is in the range from 0.8 to 3.0. In another embodiment the invention is concerned with compounds wherein the number of H-bond donors is 0, 1 , 2 or 3.
In another embodiment the invention is concerned with compounds wherein the number of H-bond donors is 0, 1 , or 2.
In another embodiment the invention is concerned with compounds wherein the number of H-bond acceptors is in the range from 4 to 9. In another embodiment the invention is concerned with compounds wherein the number of H-bond acceptors is in the range from 6 to 8.
In another embodiment the invention is concerned with compounds wherein the number of rotatable bonds of said compound is in the range from 4 to 14. In another embodiment the invention is concerned with compounds wherein the number of rotatable bonds of said compound is in the range from 8 to 12. In another embodiment the invention is concerned with compounds wherein the polar surface area (PSA) is in the range from 50 A2 to120 A2.
In another embodiment the invention is concerned with compounds wherein the polar surface area (PSA) is in the range from 60 A2 to100 A2.
In another embodiment the invention is concerned with a compound selected from the group consisting of
[Methyl-phenyl-carbamic acid 5-[2-(4,4-dimethyI-2,6-dioxo-piperidin-1 -yl)-ethyl]-pyridin-2-yl ester], [[6-(Methyl-phenyl-carbamoyloxy)-pyridin-3-ylamino]-acetic acid ferf-butyl ester],
[[6-(Methyl-phenyl-carbamoyloxy)-pyridin-3-ylamino]-acetic acid],
[Methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester],
[Methyi-phenyl-carbamic acid 5-(5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester],
[[6-(Methyl-phenyl-carbamoyloxy)-pyridin-3-ylamino]-acetic acid methyl ester],
[Methyl-phenyl-carbamic acid 5-(4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1 -y I )-py rid i n-2-y I ester],
[Methyl-phenyl-carbamic acid 5-(4-ethyl-5-oxo-2-thioxo-imidazolidin-1-yI)-pyridin-2-yl ester],
[(S)-Methyl-phenyl-carbamic acid 5-(4-isopropyl-5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-tert-butoxymethyl-5-oxo-2-thioxo-imidazolidin-1 -yl)-pyridin- 2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-feAf-butyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[3-(2,2-dimethyl-propyl)-thioureido]-pyridin-2-yl ester],
[Methyi-phenyl-carbamic acid 5-(3-isopropyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3,3-diethyl-thioureido)-pyridin-2-yI ester],
[Methyl-phenyl-carbamic acid 5-(3-cyclohexyI-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-butyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-isobutyl-thioureido)-pyridin-2-yl ester], [Methyl-phenyl-carbamic acid 5-(4-cyano-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-methyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-fluoro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-methoxy-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-methoxy-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3,4-dichloro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-methyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-bromc-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-cyano-benzoyIamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-trifIuoromethoxy-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-fluoro-3-trifluoromethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-trifluoromethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3,4-difluoro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-dimethylamino-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-dimethylamino-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-nitro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-aminc-benzoyIamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-ferf-butyl-ureido)-pyridin-2-yl ester], [Methyl-phenyl-carbamic acid 5-(4-formyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-morpholin-4-ylmethyl-benzoylamino)-pyridin-2-yI ester],
[Methyl-phenyl-carbamic acid 5-(4-hydroxymethyI-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-piperidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(4-methyl-piperidin-1 -yimethyl)-benzoylamino]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(2-ethyl-piperidin-1 -ylmethyl)-benzoylamino]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(2-methyl-piperidin-1 -yimethyl)-benzoyIamino]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(3-methyl-piperidin-1 -y!methyl)-benzoylamino]-pyridin-2-yl ester],
Methyl-phenyl-carbamic acid 5-(4-piperidin-1-yl-benzoylamino)-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-[4-(2-methyl-piperidin-1 -yl)-benzoylamino]-pyridin-2- yl ester,
Methyl-phenyl-carbamic acid 5-[4-(3-methyl-piperidin-1-yl)-benzoylamino]-pyridin-2- yl ester Methyl-phenyl-carbamic acid 5-[4-(4-methyl-piperidin-1-yl)-benzoylamino]-pyridin-2- yl ester
Methyl-phenyl-carbamic acid 4-[4-(2-ethyl-piperidin-1-yl)-benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(4,4-dimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,6-dimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester Methyl-phenyl-carbamic acid 4-[4-(2,4,6-trimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,6-dimethyl-piperidin-1 -ylmethyl)-benzoylamino]- pyridin-2-yl ester Methyl-phenyl-carbamic acid 4-[4-(4,4-dimethyl-piperidin-1-ylmethyl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,4,6-trimethyl-piperidin-1 -ylmethyl)- benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-[4-(2-piperidin-1 -yl-ethyl)-benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2-methyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(3-methyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester Methyl-phenyl-carbamic acid 5-{4-[2-(4-methyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2-ethyI-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(4,4-dimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2,6-dimethyl-piperidin-1-yl)-ethyl]- benzoylamino}-pyridin-2-yI ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2,4,6-trimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yl ester
In another embodiment the present invention relates to a compound selected from the group consisting of
Methyl-phenyl-carbamic acid 5-(4-dimethylaminomethyl-benzoylamino)-pyridin-2-yl es- ter.Methyl-phenyl-carbamic acid 5-(4-diethylaminomethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoyIamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-dipropylaminomethyl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester,
c/s-Methyl-phenyl-carbamic acid 5-[4-(2,6-dimethyl-piperidin-1 -ylmethyl)-benzoylamino]- pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[4-(4-oxo-piperidin-1-ylmethyl)-benzoylamino]-pyridin-2-yI ester,
c/s-Methyl-phenyl-carbamic acid 5-[4-(2,6-dimethyl-morpholin-4-ylmethyl)-benzoylamino]- pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-thiomorpholin-4-ylmethyl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[3-(2-hydroxy-1 ,1-dimethyl-ethyl)-thioureido]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[3-(1-methyl-cyclopropyl)-thioureido]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[3-(1-methyl-cycIobutyl)-thioureido]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-imidazol-1-yl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-diethylamino-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-[1 ,2,4]triazol-1-yl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(3,3-dipropyl-thioureido)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(3,3-dibutyl-thioureido)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[(piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(4-methyl-piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[(4,4-dimethyl-piperidine-1 -carbothioyl)-amino]-pyridin-2-yl ester,
(4-Bromo-phenyl)-methyl-carbarnic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
(4-Chloro-phenyl)-methyl-carbamic acid 4,4-dirnethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
(3,4-Dichloro-phenyl)-methyI-carbarnic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1 ,3']bipyridinyl-6'-yl ester,
(S-Chloro-phenyO-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
Methyl-p-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/-[1 ,3']bipyridinyl-6'- yl ester,
(3-Fluoro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1 ,3']bipyridinyl-6'-yl ester,
Methyl-m-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/-[1,3']bipyridinyl-6'- yl ester,
(4-Methoxy-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
(S-Methoxy-phenyO-methyl-carbamic acid 4,4-dimethyI-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1 ,3'] bipyrid i nyI-6'-yl ester,
Methyl-(3-trifluorornethyl-phenyl)-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2H-[1 ,3']bipyridinyl-6'-yl ester, (3-Bromo-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1.S'Jbipyridinyl-δ'-yl ester,
(4-Fluoro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1 ,3']bipyridinyl-6'-yl ester,
[4-(2-Hydroxy-ethyl)-phenyl]-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2H-[1 ,3']bipyridinyI-6'-yl ester,
In another aspect the present invention relates to a pharmaceutical composition comprising a compound of general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
In one embodiment the invention is concerned with a pharmaceutical composition in unit dosage form, comprising from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of said compound according to the invention or pharmaceutically acceptable salt thereof.
In another embodiment the invention is concerned with a pharmaceutical composition for use as a medicament for inhibiting the lipolytic activity of hormone-sensitive lipase against triacyl- glycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters, said composition comprising a compound according to the invention or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
In another embodiment the invention is concerned with a pharmaceutical composition which is for oral administration. In another embodiment the invention is concerned with a pharmaceutical composition which is for nasal, transdermal, pulmonal, or parenteral administration.
In another aspect the present invention relates to use of a compound according to the invent- tion for the preparation of a pharmaceutical composition. In one embodiment the invention is concerned with use of a compound according to the invention for inhibition of hormone sensitive lipase.
In another embodiment the invention is concerned with use of a compound according to the invention for preparation of a pharmaceutical composition for inhibition of the lipolytic activity of hormone-sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters.
In another embodiment the invention is concerned with use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment or prevention of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and/or modulate intracellular triacylglycerol and cholesterol ester stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA; and/or increase insulin sensitivity in adipose tissue, skeletal muscle, liver or pancreatic β cells; and/or modulate insulin secretion from pancreatic β cells.
In another embodiment the invention is concerned with the above use wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 , diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism and any combination thereof.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of dyslipidemia.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of hyperlipidemia.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of hyperglycemia.
In another embodiment the invention is concerned with the use of a compound according to the invention for lowering HbA10. In another embodiment the invention is concerned with the preparation of a pharmaceutical composition for the treatment and/or prevention of diabetes type 2.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention impaired glucose tolerance.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of metabolic syndrome X.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for the treatment and/or prevention of atheroschlerosis.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for delaying or prevention of the progression from impaired glucose tolerance to diabetes type 2.
In another embodiment the invention is concerned with the use of a compound according to the invention for the preparation of a pharmaceutical composition for delaying or prevention of the progression from non-insulin requiring diabetes type 2 to insulin requiring diabetes type 2.
In another embodiment the invention is concerned with the use according to above indica- tionns wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is used.
In another embodiment the invention is concerned with the use according to above indications, wherein metformin is also used.
In another aspect the present invention is related to a method of treating a disorder of a patient where modulation of the activity of hormone-sensitive lipase is desired, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof.
In one embodiment the invention is concerned with a method of treating a disorder of a patient where lowering of the activity of hormone-sensitive lipase is desired, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to the invention or a pharmaceutically acceptable salt thereof.
In another embodiment the invention is concerned with the above methods wherein said administration is carried out by the oral, nasal, transdermal, pulmonal, or parenteral route.
In another embodiment the invention is concerned with the above methods wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 , diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atherosclerosis, hypertension, abnormalities of lipoprotein metabolism and any combination thereof.
In another embodiment the invention is concerned with the above methods wherein the therapeutically effective amount of the compound is from about 0.05 to about 2000 mg, pref- erably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of said compound per day.
In another embodiment the invention is concerned with the above methods wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is administered to the patient.
In another embodiment the invention is concerned with above methods wherein metformin is also administered to the patient.
In another aspect the present invention is related to a process P1 for the preparation of a compound of the invention or its pharmaceutically acceptable salt, which comprises reacting the appropriate alcohol with the appropriate carbamoylating reagent in a solvent according to the reaction scheme P1 and isolating the disubstituted carbamate product.
In one embodiment of the invention wherein said carbamoylating reagent
is selected from the group consisting of
In another embodiment of the invention said solvent is selected from the group consisting of tetrahydrofurane, dimethylformamide and N-methylpyrolidone.
In another embodiment of the invention said base is selected from the group consisting of triethylamine, N,N-diisopropyl-N-ethylamine and DABCO.
In another aspect the present invention relates to a process P2 for the preparation of a compound of the invention, said process comprising the treatment of the appropriate amine with the appropriate acylating reagent in a solvent and in the presence of a base according to the reaction scheme P2
and isolating the disubstituted carbamate
In one embodiment of the invention Lv is CI. In another embodiment of the invention said solvent is selected from the group consisting of diethyl ether, tetrahydrofuran and dichloromethane.
In another embodiment of the invention said base is selected from the group consisting of trimethylamine, triethylamine, ethyl-diisopropyl-amine and 1 ,4-diazabicyclo[2.2.2]octane. In another embodiment of the invention said base is present as a functionality in one or both of the substituents R3 and R4, thus forming a salt with the acid H-Lv.
The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, parnoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaph- thoates, glycerophosphates, ketoglutarates and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium, zinc, calcium salts and the like. Examples of amines and organic amines include ammonium, methylamine, di- methylamine, trimethylamine, ethylamine, diethylamine, propylamine, butylamine, tetrame- thylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, choline, N,N'-dibenzylethylenediamine, N-benzylphenylethylamine, N-methyl-D-glucamine, guanidine and the like. Examples of cationic amino acids include lysine, arginine, histidine and the like.
The pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, enzymatic resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, (R)- or (S)-phenylethylamine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981). More specifically the compound of formula I may be converted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydrolysing the pure diastereomeric amide.
Various polymorphs of compound of general formula I forming part of this invention may be prepared by crystallization of compound of formula I under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calo- rimetry, powder X-ray diffraction or such other techniques.
The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula I. Conventional procedures for the selection and preparation of suitable prodrug de- rivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
The invention also encompasses active metabolites of the present compounds.
The invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the formula I or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.
Furthermore, the invention relates to the use of compounds of the general formula I or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically ac- ceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of disorders where a decreased level of plasma FFA is desirable, such as the conditions mentioned above.
In another aspect, the present invention relates to a method of treating and/or preventing type 2 diabetes, insulin resistance, metabolic syndrome X, impaired glucose tolerance, dyslipidemia and abnormalities of lipoprotein metabolism.
In a still further aspect, the present invention relates to the use of one or more compounds of the general formula I, or pharmaceutically acceptable salts thereof, for the preparation of a pharmaceutical composition for the treatment and/or prevention of type 2 diabetes, insulin resistance, metabolic syndrome X, impaired glucose tolerance, dyslipidemia and abnormalities of lipoprotein metabolism.
In a still further aspect, the present compounds are useful for the delaying or prevention of the progression from impaired glucose tolerance to type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes.
In another aspect, the present compounds reduce triglyceride levels and are accordingly useful for the treatment and/or prevention of ailments and disorders such as diabetes and/or obesity.
In still another aspect, the compounds of general formula I are useful for the treatment of hy- perglycemia, elevated HbA10 level, hyperinsulinemia, type 1.5 diabetes, latent autoimmune diabetes in adults, maturity onset diabetes, beta-cell apoptosis, hemochromatosis induced diabetes, impaired glucose tolerance, impaired fasting glucose, metabolic syndrome X, insulin resistance, impaired lipid tolerance, cystic fibrosis related diabetes, polycystic ovarian syndrome, and gestational diabetes. In still another aspect, the compounds of general formula I are useful for the treatment of obesity, dyslipidemia, diabetic dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, hypertension, essential hypertension, acute hypertensive emergency, arteriosclerosis, atherosclerosis, restenosis, intermittent claudication (atherosclerosis oblitterens), cardiovascular disease, cardiomyopathy, cardiac hypertrophy, left ventricular hypertrophy, coronary artery disease, early coronary artery disease, heart insufficiency, exercise tolerance, chronic heart failure, mild chronic heart failure, arrhythmia, cardiac dysrythmia, syncopy, heart attack, myocardial infarction, Q-wave myocardial infarction, stroke, acute coronary syndrome, angina pectoris, unstable angina, cardiac bypass re- occlusion, diastolic dysfunction, systolic dysfunction, non-Q-wave cardiac necrosis, catabolic changes after surgery, acute pancreatitis, and irritable bowel syndrome
In still another aspect, the compounds of general formula I may be useful for the treatment of diabetic retinopathy, background retinopathy, preproliferative retinopathy, prolif- erative retinopathy, macular edema, cataracts, nephropathy, nephrotic syndrome, diabetic nephropathy, microalbuminuria, macroalbuminuria, neuropathy, diabetic neuropathy, distal symmetrical sensorimotor polyneuropathy, and diabetic autonomic neuropathy.
In still another aspect, the compounds of general formula I are useful for increasing the number of beta-cells in a patient, increasing the size of beta-cells in a patient or stimulating beta-cell proliferation, modulating beta-cell function and insulin secretion in a patient in need thereof, which method comprises administration of an effective amount of a compound of formula I to a patient in need thereof.
The compounds of the invention are also believed to be useful for reducing body weight in a patient in need thereof.
The compounds of the invention are also believed to be useful for weight neutral treatment of above mentioned diseases.
The compounds of the invention are also believed to be useful for redistributing fat in a pa- tient in need thereof.
The compounds of the invention are also believed to be useful for redistributing central fat in a patient in need thereof.
The compounds of the invention are also believed to be useful for reducing or preventing central obesity. The compounds of the invention are also believed to be useful for reducing postprandial serum lipid excursions.
The compounds of the invention are also believed to be useful for the treatment of fatty acid oxidation disorders such as MCAD.
In still another aspect, the compounds of general formula I are believed to be useful for the treatment of a disease, condition or disorder wherein cholesterol is a precursor. Such diseases, conditions or disorders may relate to testosterone, e.g. male contraception, excessive testosterone levels, PCOS and prostate cancer. They may also relate to Cortisol or cortico- tropin, e.g. Cushing disease.
The compounds of the invention are also believed to be useful for the treatment of cancer. Thus, the compounds of the general formula I may be useful for the treatment of insulinoma (pancreatic islet cell tumors), e.g. malignant insulinomas and multiple insulinomas, adipose cell carcinomas, e.g. lipocarconoma. The compounds of the invention are also believed to be useful for the treatment of phaechromocytoma and other diseases with increased catecholamine incretion. The compounds of the invention are also believed to be useful for the treatment of prostate cancer, e.g. adenocarcinoma.
In still another aspect, the compounds of general formula I may be useful for the treatment of hepatic steatosis.
In still another aspect, the compounds of general formula I may be useful for the treatment of cirrhosis. In still another aspect, the compounds of general formula I may be useful for the treatment of AIDS or an AIDS related diseases, condition or disorders
In still another aspect, the compounds of general formula I may be useful for the treatment of lipodystrophy
In still another aspect, the compounds of general formula I may be useful for the treatment of lactic acidosis. In yet another aspect, the compounds of the present invention are expected to be useful for the treatment of CNS diseases, conditions or disorders.
Thus, the compound of the present invention may be used for the treatment of Parkinsons disease, Alzheimers disease, ADHD (Attention Deficit Hyperactivity Disorder), feeding disorders such as bulimia and anorexia, depression, anxiety, cognitive memory disorders, age related cognitive decline, mild cognitive impairment and schizophrenia. In yet another aspect, the compounds of the present invention may be useful for the treatment of inflammatory disorders, e.g. rheumatoid arthritis, psoriasis, systemic inflammatory response syndrome, sepsis and the like.
The present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the treatment and/or prevention of complications re- suiting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
Thus, in a further aspect of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART (cocaine am- phetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melano- cortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, se- rotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid X recep- tor) modulators or TR β agonists.
In one embodiment of the invention the antiobesity agent is leptin.
In another embodiment the antiobesity agent is dexamphetamine or amphetamine.
In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine.
In still another embodiment the antiobesity agent is sibutramine. In a further embodiment the antiobesity agent is orlistat.
In another embodiment the antiobesity agent is mazindol or phentermine.
Suitable antidiabetics comprise insulin, exendin-4, GLP-1 (glucagon like peptide-1) and derivatives thereof such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents. The orally active hypoglycaemic agents preferably comprise sulphonylureas, bigua- nides, meglitinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase- IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenosis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potas- sium channel of the β-cells.
In one embodiment of the invention the present compounds are administered in combination with insulin.
In a further embodiment the present compounds are administered in combination with a sulphonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide. In another embodiment the present compounds are administered in combination with a biguanide eg. metformin.
In yet another embodiment the present compounds are administered in combination with a meglitinide eg. repaglinide or senaglinide.
In a further embodiment the present compounds are administered in combination with an α-glucosidase inhibitor eg. miglitol or acarbose.
In another embodiment the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
Furthermore, the present compounds may be administered in combination with nateglinide.
In still another embodiment the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofi- brate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
In a further embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds eg. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin con- verting enzyme) inhibitors such as benazepril, captopril, alatriopril, enalapril, fosinopril, lisi- nopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
The present invention also relates to processes according to reaction schemes P1 and P2 for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceu- tically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacol 9th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route be- ing preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.
Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropri- ate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well-known in the art.
Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs. Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention. Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.
The therapeutic dose of the compound will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art. The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. In one embodiment the composition in unit dosage form, comprises from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg of the compound of formula I pharmaceutically acceptable salt thereof. In a still further embodiment the pharmaceutical composition is for oral, nasal, transdermal, pulmonal, or parenteral administration.
For parenteral routes, such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration. The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. One example is an acid addition salt of a compound having the utility of a free base. When a compound of the invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the compound with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids. Representative examples are mentioned above. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion.
For parenteral administration, solutions of the present compounds in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
The pharmaceutical compositions formed by combining the compounds of the invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may con- veniently be presented in unit dosage form by methods known in the art of pharmacy.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emul- sion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
A typical tablet which may be prepared by conventional tabletting techniques may contain:
Core: Active compound (as free compound or salt thereof) 5 mg Colloidal silicon dioxide (Aerosil) 1.5 mg
Cellulose, microcryst. (Avicel) 70 mg
Modified cellulose gum (Ac-Di-SoI) 7.5 mg
Magnesium stearate q.s.
Coating:
HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg
*AcyIated monoglyceride used as plasticizer for film coating.
The compounds of the invention may be administered to a patient which is a mammal, especially a human in need thereof. Such mammals include also animals, both domestic animals, e.g. household pets, and non-domestic animals such as wildlife. In a further aspect of the invention the present compounds may be administered in combination with further pharmacologically active substances e.g. an antidiabetic or other pharmacologically active material, including other compounds for the treatment and/or prevention of insulin resistance and diseases, wherein insulin resistance is the pathophysiological mechanism. Furthermore, the compounds according to the invention may be administered in combination with antiobesity agents or appetite regulating agents.
EXAMPLES
Starting materials For the synthesis of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester, Λ/-(6- hydroxy-pyridin-3-yl)~benzamide and 6'-hydroxy-4,4-dimethyl-4,5-dihydro-3H-[1 ,3']bipyridinyl- 2,6-dione see; PCT/DK02/00852. For the synthesis of (6-methoxy-pyridin-3-yl)-methanol see e.g.; Alan P. Kozikowski, Yan Xia, E. Rajarathnam Reddy, Werner Tuckmantel, Israel Hanin, and X. C. Tang J. Org. Chem. 1991 , 56, 4636 - 4645. Example 1
[Methyl-phenyl-carbamic acid 5-[2-(4,4-dimethyl-2,6-dioxo-piperidin-1 -y I )-ethy l]-pyri d in-2-yl ester]
Step A: Thionyl chloride (100 mL) was added to a stirred solution of (6-methoxy-pyridin-3- yl)-methanol (31.0 g, 223 mmol) in chloroform (300 mL). After refluxing for 2 hours, the solvent and excess thionyl chloride were removed by evaporation in vacuo. The residue was stripped with toluene, dissolved in dichloromethane (400 mL) and extracted with a saturated aqueous sodium bicarbonate solution (200 mL). The organic layer was dried over sodium sulphate, filtered and evaporated in vacuo, yielding a yellow oil. The oil was dissolved in di- methylformamide (750 mL), followed by the addition of potassium cyanide (14.5 g, 223 mmol). After stirring overnight at room temperature, the reaction mixture was poured into water (1.5 L). Ethyl acetate (500 mL) was added and both layers were separated. The water layer was extracted with ethyl acetate (4 x 200 mL) and the combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The product was purified by flash column chromatography (SiO2, ethyl acetate/heptane 1/2) yielding (6-methoxy-pyridin- 3-yl)-acetonitrile (13.7 g, 42% yield).
1H NMR (200 MHz, CDCI3): δ= 3.75 (s, 2H), 4.00 (s, 3H), 6.85 (d, 1 H), 7.60 (dd, 1H), 8.15 (br.s, 1H); Step B:
Borane-tetrahydrofuran complex (1 M solution in tetrahydrofuran, 350 mL) was added to a stirred solution of (6-methoxy-pyridin-3-yl)-acetonitrile (13.7 g, 92.5 mmol) in tetrahydrofuran (130 mL). After stirring overnight at 60 0C, 1 N aqueous hydrochloric acid (80 mL) was added. The resulting mixture was heated at reflux for 2 hours followed by cooling to room temperature. The solution was washed with fe/Y-butyl methyl ether. 9N aqueous sodium hydroxide (60 mL) was added to the water layer followed by extraction with dichloromethane (4 x 200 mL). The combined organic layers were dried over sodium sulphate/potassium carbonate 1/1 , filtered and evaporated in vacuo, yielding an oil, which was redissolved in dichloromethane (100 mL). A 4 M solution of hydrochloric acid in dioxane was added. The white precipitate was isolated by filtration and dried, yielding 2-(6-methoxy-pyridin-3-yl)- ethylamine dihydrochloride (10.2 g, 49% yield).
1H NMR (200 MHz, CDCI3): δ= 2.80-2.96 (m, 2H), 2.98-3.14 (m, 2H), 6.86 (d, 1 H), 7.27 (dd, 1 H), 8.12 (d, 1 H), 8.20 (br.s, 2H). Step C:
A solution of 2-(6-methoxy-pyridin-3-yl)-ethylamine dihydrochloride (0.94 g, 4.18 mmol), 3,3-dimethylglutaric anhydride (0.71 g, 4.99 mmol) and triethylamine (1.16 ml_, 8.35 mmol) in dichloromethane was stirred at room temperature for 30 minutes. 1 ,1'-Carbonyl- diimidazole (0.68 g, 4.18 mmol) was added and the solution was refluxed for 2 hours followed by stirring overnight at room temperature. An additional small amount of 1 ,1'- carbonyldiimidazole was added and reflux was continued for 3 hours. The solution was extracted twice with water, dried over sodium sulphate, filtered and evaporated in vacuo, yielding 1-[2-(6-methoxy-pyridin-3-yl)-ethyl]-4,4-dimethyl-piperidine-2,6-dione (1.22 g, 106% yield) as a colourless oil that solidified upon standing.
1H NMR (300 MHz, CDCI3): δ= 1.04 (s, 6H), 2.48 (s, 4H), 2.74 (m, 2H), 3.91 (s, 3H), 3.96 (m, 2H), 6.68 (d, 1H), 7.50 (dd, 1H), 7.98 (d, 1H); HPLC-MS (Method A): m/z = 277 (M+H)+; Rt = 2.72.
Step D: During 5 minutes HCI-gas was bubbled into a solution of 1-[2-(6-methoxy-pyridin-3- yl)-ethyl]-4,4-dimethyl-piperidine-2,6-dione (1.15 g, 4.18 mmol) in tetrahydrofuran (25 mL). Ether (200 mL) was added and the solvent was evaporated in vacuo. The residue was heated for 5 minutes at 180 0C. After cooling to room temperature the solid was dissolved in dichloromethane (10 mL). 1 ,4-Diazabicyclo[2.2.2]octane (0.47 g, 4.18 mmol) and Λ/-methyl- Λ/-phenylcarbamoyI chloride (0.71 g, 4.18 mmol) were added. After stirring for 30 minutes at room temperature, the product was purified by flash column chromatography (SiO2, ethyl acetate/heptane 60/40) yielding the title compound (0.42 g, 25% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 1.04 (s, 6H), 2.48 (s, 4H), 2.82 (m, 2H), 3.43 (br.s, 3H), 3.99 (m, 2H), 7.00 (br.s, 1 H), 7.26 (m, 1 H), 7.39 (d, 4H), 7.68 (dd, 1 H), 8.20 (d, 1 H); HPLC-MS (Method A): m/z = 396 (M+H)+; Rt = 3.60 min.
Example 2
[^-(Methyl-phenyl-carbamoyloxyJ-pyridin-S-ylaminoj-acetic acid ferf-butyl ester]
A mixture of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (2.43 g, 10.0 mmol), bromoacetic acid ferf-butylester (3.90 g, 20.0 mmol), potassium carbonate (5.52 g, 40.0 mmol) and a catalytic amount of 18-crown-6 in toluene (50 mL) was stirred for 4 days at room temperature. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50) yielding the title compound (0.67 g, 19% yield) as an oil.
1H NMR (300 MHz, CDCI3): δ- 1.50 (s, 9H), 3.42 (br.s, 3H), 3.79 (s, 2H), 4.30 (br.s, 1 H), 6.83-7.00 (m, 2H), 7.39 (m, 4H), 7.70 (d, 1 H); HPLC-MS (Method A): m/z = 358 (M+H)+; Rt = 3.74 min.
Example 3
[[6-(Methyl-phenyl-carbamoyloxy)-pyridin-3-ylamino]-acetic acid]
A solution of [δ^methyl-phenyl-carbamoyloxyJ-pyridin-S-ylaminol-acetic acid tert- butyl ester (0.60 g, 1.68 mmol) in 20% trifluoroacetic acid in dichloromethane (25 mL) was stirred at room temperature for 3 hours. The solvent was evaporated in vacuo yielding a solid, which was heated briefly with a small amount of ethyl acetate. After cooling to room temperature the solid was isolated by suction, yielding the title compound (0.42 g, 82% yield) as a white solid. 1H NMR (300 MHz, DMSO-d6): δ= 3.33 (s, 3H), 3.89 (s, 2H), 6.96 (d, 1H), 7.14 (dd, 1 H), 7.27 (m, 1 H), 7.43 (m, 4H), 7.66 (d, 1H), 11.60 (br.s, 1H); HPLC-MS (Method A): m/z = 302 (M+H)+; Rt = 2.50 min.
Example 4
[Methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (2.43 g, 10.0 mmol) and di-2-pyridyl thionocarbonate (2.32 g, 10.0 mmol) in dichloropropane (25 mL) was stirred at room temperature for 2 hours. The solution was used as such, without isolation of the product. HPLC-MS (Method A): mlz = 308 (M+Na)+; Rt = 4.08 min.
Example 5
[Methyl-phenyl-carbamic acid 5-(5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester]
Glycine hydrochloride (2.00 mmol, 251 mg) was added to a solution of methyl- phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.00 mmol) in 1 ,2- dichloropropane (5 ml_). A few millilitres of methanol were added to get a clear solution. Triethylamine (0.28 ml_, 2.00 mmol) was added and the solution was stirred overnight at room temperature. Dichloromethane was added and the reaction mixture was extracted twice with water, dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 70/30), yielding the title compound (0.27 g, 40% yield) as a solid.
1H NMR (300 MHz, CDCI3): δ= 3.46 (br.s, 3H), 4.14 (s, 2H), 7.17 (m, 1H), 7.27 (m, 1 H), 7.39 (m, 4H), 7.75 (m, 2H), 8.39 (s, 1 H); HPLC-MS (Method A): m/z = 375 (M+H)+; Rt = 2.64 min.
Example 6 [[6-(MethyI-phenyl-carbamoyIoxy)-pyridin-3-ylamino]-acetic acid methyl ester]
A mixture of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (2.43 g, 10.0 mmol), bromoacetic acid methylester (3.06 g, 20.0 mmol), potassium carbonate (5.52 g, 40.0 mmol) and a catalytic amount of 18-crown-6 in toluene (50 ml_) was stirred for 3 days at room temperature. The solution was extracted twice with water, dried over sodium sulphate, filtered and evaporated in vacuo. The residue was crystallised from ethyl acetate/heptane, yielding the title compound (0.62 g, 20% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 3.42 (br.s, 3H), 3.77 (s, 3H), 3.89 (s, 2H), 4.38 (br.s, 1H), 6.89 (m, 1H), 6.96 (dd, 1H), 7.24 (m, 1H), 7.37 (m, 4H), 7.70 (d, 1 H); HPLC-MS (Method A): m/z = 316 (M+H)+; Rt = 2.87 min.
Example 7
[Methyl-phenyl-carbamic acid 5-(4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1 -yl)-pyridin-2-yl ester]
Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (1.22 g, 5.00 mmol) was added in portions to a stirred solution of di-2-pyridyl thionocarbonate (1.16 g, 5.00 mmol) in 1 ,2-dichIoropropane (15 mL). After stirring for 1 hour at room temperature, alpha- aminoisobutyric acid methyl ester hydrochloride (0.77 g, 5.00 mmol) and triethylamine (0.7 mL) were added, together with some dimethylformamide to get a clear solution. After stand- ing overnight the solvent was evaporated in vacuo and the residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50), yielding the title compound (1.30 g, 70% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 1.48 (s, 6H), 3.45 (br.s, 3H), 7.19 (br.s, 1 H), 7.28 (m, 1H), 7.39 (m, 4H), 7.79 (br.d, 1 H), 8.35 (s, 1H, NH), 8.39 (s, 1H); HPLC-MS (Method A): m/z = 371 (M+H)+; Rt = 3.37 min.
Example 8 [Methyl-phenyl-carbamic acid 5-(4-ethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester]
DL-alpha-amino-n-butyric acid methyl ester hydrochloride (2.00 mmol, 307 mg) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.00 mmol) in 1,2-dichloropropane (5 mL). A small amount of methanol was added to get a clear solution. Triethylamine (0.28 mL, 2.00 mmol) was added and the solution was stirred overnight at room temperature. Dichloromethane was added and the reaction mixture was extracted twice with water, dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50), yielding the title compound (0.25 g, 33% yield) as a white solid. 1H NMR (300 MHz, CDCI3): J= 1.00 (t, 3H), 1.90 (m, 2H), 3.43 (br.s, 3H), 4.17 (t, 1 H), 7.17 (br.s, 1H), 7.28 (m, 1 H), 7.39 (m, 4H), 7.74 (br.d, 1H), 8.30 (s, 1 H), 8.36 (s, 1 H); HPLC-MS (Method A): m/z = 371 (M+H)+; Rt = 3.39 min.
Example 9
[(S)-Methyl-phenyl-carbamic acid 5-(4-isopropyl-5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester]
L-Valine methyl ester hydrochloride (2.00 mmol, 307 mg) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.00 mmol) in 1 ,2- dichloropropane (5 mL). A small amount of methanol was added to get a clear solution. Triethylamine (0.28 mL, 2.00 mmol) was added and the solution was stirred overnight at room temperature. Dichloromethane was added and the reaction mixture was extracted twice with water, dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50), yielding the title compound (139 mg, 18% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 0.98 (d, 3H), 1.07 (d, 3H), 2.30 (m, 1H), 3.43 (br.s, 3H), 4.10 (d, 1 H), 7.18 (br.s, 1H), 7.27 (m, 1 H), 7.39 (m, 4H), 7.72 (br.d, 1 H), 8.32 (s, 1H), 8.50 (s, 1H); HPLC-MS (Method A): m/z = 385 (M+H)+; Rt = 3.62 min. Example 10
[Methyl-phenyl-carbamic acid 5-(4-tert-butoxymethyl-5-oxo-2-thioxo-imidazolidin-1 -yl)-pyridin- 2-yl ester]
O-M3utyl-D-serine acid methyl ester hydrochloride (2.00 mmol, 307 mg) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.00 mmol) in dichloromethane (10 ml_). Triethylamine (0.28 mL, 2.00 mmol) was added and the solution was stirred for 7 days at room temperature. Part of the solvent was removed by evaporation in vacuo. The residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50) yielding the title compound (430 mg, 50% yield) as a white foam. 1H NMR (300 MHz, CDCI3): δ= 1.18 (s, 9H), 3.45 (br.s, 3H), 3.70 (dd, 1H), 3.80 (dd, 1 H), 4.36 (dd, 1 H), 7.18 (br.s, 1 H), 7.29 (m, 1H), 7.39 (m, 4H), 7.73 (br.d, 1 H), 7.90 (br.s, 1 H), 8.34 (br.s, 1H); HPLC-MS (Method A): m/z = 429 (M+H)+; Rt = 3.88 min.
Example 11 [Methyl-phenyl-carbamic acid 5-(3-fe/ϊ-butyl-thioureido)-pyridin-2-yl ester]
A solution of ferf-butylamine (146 mg, 2.0 mmol) in dichloromethane (5 mL) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.0 mmol) in dichloromethane (5 mL). The solution was stirred for 1 hour at room tempera- ture. Without further work-up, the reaction mixture was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50), yielding the title compound (542 mg, 76% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 1.43 (s, 9H), 3.43 + 3.50 (2 x br.s, 3H)1 6.27 + 6.41 (2 x br.s, 1H), 6.96 + 7.06 (2 x br.s, 1 H), 7.25-7.44 (m, 5H), 7.68 + 7.78 (2 x br.s, 2H), 8.00 (br.s, 1H); HPLC-MS (Method A): mlz = 359 (M+H)+; Rt = 3.74 min.
Example 12
[Methyl-phenyl-carbamic acid 5-[3-(2,2-dimethyI-propyl)-thioureido]-pyridin-2-yl ester]
A solution of 2,2-dimethylpropylamine (174 mg, 2.0 mmol) in dichloromethane (5 mL) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.0 mmol) in dichloromethane (5 mL). The solution was stirred for 1 hour at room temperature. Without further work-up, the reaction mixture was purified by flash column chromatography (SiO2, ethyl acetate/heptane 50/50), yielding the title compound (674 mg, 90% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 0.89 (s, 9H), 3.33-3.60 (br.m, 5H), 6.59 + 6.70 (2 x br.s, 1 H), 6.88 + 7.01 (2 x br.s, 1 H), 7.26-7.45 (m, 5H), 7.75-8.26 (5 x br.s, 3H); HPLC-MS (Method A): ' mlz = 373 (M+H)+; Rt = 4.10 min.
Example 13
[Methyl-phenyl-carbamic acid 5-(3-isopropyl-thioureido)-pyridin-2-yl ester]
A solution of isopropylamine (118 mg, 2.0 mmol) in dichloromethane (5 ml_) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.0 mmol) in dichloromethane (5 ml_). The solution was stirred for 1 hour at room temperature. Without further work-up, the product was purified by flash column chromatography (SiO2, ethyl acetate/heptane (50/50), yielding the title compound (560 mg, 81% yield) as a white solid.
1H NMR (300 MHz, CDCl3): 5= 1.08 (d, 6H), 3.45 + 3.52 (2 x br.s, 3H), 4.47 (octet, 1H), 6.38 + 6.60 (2 x br.s, 1 H), 6.90 + 7.03 (2 x br.s, 1 H), 7.26- 7.50 (m, 5H), 7.68-8.02 (3 x br.s, 3H); HPLC-MS (Method A): mlz = 345 (M+H)+; Rt = 3.35 min.
Example 14 [Methyl-phenyl-carbamic acid 5-(3,3-diethyl-thioureido)-pyridin-2-yl ester]
A solution of diethylamine (146 mg, 2.0 mmol) in dichloromethane (5 mL) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.0 mmol) in dichloromethane (5 mL). The solution was stirred for 1 hour at room temperature. Without further work-up, the product was purified by flash column chromatography (SiO2, ethyl acetate/heptane (50/50), yielding the title compound (196 mg, 27% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 1.27 (t, 6H), 3.42 (br.s, 3H), 3.75 (q, 4H), 6.91 (br.s, 1 H), 7.26 (m, 1 H), 7.37 (m, 5H), 7.78 (br.d, 1H), 8.12 (br.s, 1 H); HPLC-MS (Method A): m/z = 359 (M+H)+; Rt = 3.44 min. Example 15
[Methyl-phenyl-carbamic acid 5-(3-cyclohexyl-thioureido)-pyridin-2-yl ester]
A solution of cyclohexylamine (198 mg, 2.0 mmol) in dichloromethane (5 mL) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yI ester (0.57 g, 2.0 mmol) in dichloromethane (5 mL). The solution was stirred for 1 hour at room temperature. Without further work-up, the product was purified by flash column chromatography (SiO2, ethyl acetate/heptane (60/40), yielding the title compound (554 mg, 72% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ- 0.88 (m, 2H), 1.07 (m, 1 H), 1.30 (m, 2H), 1.62 (m, 3H), 1.94 (d, 2H), 3.44 + 3.54 (2 x br.s, 3H), 4.11 (m, 1H), 6.39 + 6.62 (2 x br.s, 1H), 6.90 + 7.01 (2 x br.s, 1 H), 7.23-7.50 (m, 5H), 7.63-8.04 (br.m, 3H); HPLC-MS (Method A): m/z = 385 (M+H)+; Rt = 3.97 min.
Example 16 [Methyl-phenyl-carbamic acid 5-(3-butyl-thioureido)-pyridin-2-yl ester]
A solution of n-butylamine (146 mg, 2.0 mmol) in dichloromethane (5 mL) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.0 mmol) in dichloromethane (5 mL). The solution was stirred for 1 hour at room tempera- ture. Without further work-up, the product was purified by flash column chromatography (SiO2, ethyl acetate/heptane (70/30), yielding the title compound (627 mg, 87% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 0.90 (t, 3H), 1.20-1.47 (m, 4H), 3.42 + 3.53 (2 x br.s, 5H), 6.51 + 6.80 (2 x br.s, 1H), 6.91 + 7.04 (2 x br.s, 1H), 7.38-7.50 (m, 5H), 7.65-8.17 (3 x br.s, 3H); HPLC-MS (Method A): m/z = 359 (M+H)+; Rt = 3.70 min.
Example 17
[Methyl-phenyl-carbamic acid 5-(3-isobutyl-thioureido)-pyridin-2-yl ester]
A solution of isobutylamine (146 mg, 2.0 mmol) in dichloromethane (5 mL) was added to a solution of methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester (0.57 g, 2.0 mmol) in dichloromethane (5 mL). The solution was stirred for 1 hour at room tempera- ture. Without further work-up, the product was purified by flash column chromatography (SiO2, ethyl acetate/heptane (70/30), yielding the title compound (621 mg, 87% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 0.84 (d, 6H), 1.74 (br.s, 1 H), 3.29 (br.s, 2H), 3.42 + 3.53 (2 x br.s, 3H), 6.53 + 6.82 (2 x br.s, 1H), 6.94 + 7.06 (2 x br.s, 1 H), 7.27-7.50 (m, 5H), 7.70-8.14 (br.m, 3H); HPLC-MS (Method A): mlz = 359 (M+H)+; Rt = 3.67 min.
Example 18
[Methyl-phenyl-carbamic acid 5-(4-cyano-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 4-cyanobenzoyl chloride (91 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 ml.) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (125 mg, 67% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 3.39 + 3.53 (2 x br.s, 3H), 6.88 (br.s, 1 H), 7.27-7.48 (m, 5H), 7.63 (d, 2H), 7.98 (d, 3H), 8.34 (d, 1 H), 8.81 + 9.08 (2 x br.s, 1 H); HPLC-MS (Method A): mlz = 373 (M+H)+; Rt = 3.50 min.
Example 19
[Methyl-phenyl-carbamic acid 5-(2-methyl-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 2-methylbenzoyl chloride (85 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (361 mg, 66% yield) as an oil.
1H NMR (300 MHz, CDCI3): δ= 2.45 (s, 3H), 3.21 + 3.42 (2 x br.s, 3H), 6.90 (br.s, 1H), 7.12- 7.39 (m, 8H), 7.45 (d, 1H), 8.08 (dd, 1 H)1 8.32 (s, 1 H), 8.54 (s, 1 H); HPLC-MS (Method A): mlz = 362 (M+H)+; Rt = 3.62 min. Example 20
[Methyl-phenyl-carbamic acid 5-(4-fluoro-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5~amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 4-fluorobenzoyl chloride (87 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 ml.) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (74 mg, 41% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ~ 3.41 (br.s, 3H), 6.91 (br.s, 1H), 7.07 (m, 2H), 7.27 (m, 1 H), 7.32-7.44 (m, 4H), 7.90 (m, 2H), 8.05 (dd, 1 H), 8.33 (d, 1 H), 8.50 + 8.65 (2 x br.s, 1 H); HPLC-MS (Method A): m/z = 366 (M+H)+; Rt = 3.61 min.
Example 21
[Methyl-phenyl-carbamic acid 5-(3-methoxy-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5~amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 3-methoxybenzoyl chloride (94 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (210 mg, 111 % yield) as an oil, which solidified upon standing
1H NMR (300 MHz, CDCI3): δ= 3.40 (br.s, 3H), 3.82 (s, 3H), 6.89 (br.s, 1H), 7.05 (dd, 1H), 7.21-7.49 (m, 8H), 8.06 (br.d, 1 H), 8.39 (d, 1 H), 8.87 (br.s, 1H); HPLC-MS (Method A): m/z = 378 (M+H)+; Rt = 3.62 min.
Example 22 [Methyl-phenyl-carbamic acid 5-(2-methoxy-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 2-methoxybenzoyl chloride (94 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (109 mg, 57% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 3.44 (br.s, 3H), 4.06 (s, 3H), 7.02 (d, 1 H), 7.06 (br.s, 1 H), 7.12 (t, 1H), 7.26 (m, 1 H), 7.39 (d, 4H), 7.51 (m, 1H), 8.36 (dd, 1 H), 8.37 (m, 1 H), 8.43 (s, 1H), 9.87 (s, 1 H); HPLC-MS (Method A): m/z = 378 (M+H)+; Rt = 3.72 min.
Example 23 [Methyl-phenyl-carbamic acid 5-(3,4-dichloro-benzoyIamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 3,4-dichlorobenzoyl chloride (91 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 ml_) was stirred at room temperature for 1 hour. Dichloromethane (3 ml_) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (130 mg, 63% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ- 3.41 (br.s, 3H), 6.81 + 6.92 (2 x br.s, 1 H), 7.27 (m, 1H), 7.38 (m, 4H), 7.44 (d, 1H), 7.72 (dd, 1H), 7.92 (br.s, 1H), 8.03 (d, 1H), 8.30 (s, 1H), 8.90 (br.s, 1H); HPLC-MS (Method A): m/z = 416 (M+H)+; Rt = 4.30 min.
Example 24
[Methyl-phenyl-carbamic acid 5-(4-methyl-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 4-methylbenzoyl chloride (85 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography, yielding the title compound (157 mg, 83% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ- 2.40 (s, 3H), 3.41 (br.s, 3H), 6.90 (br.s, 1 H), 7.18 (d, 2H), 7.25 (m, 1H), 7.36 (m, 4H), 7.78 (d, 2H), 8.10 (dd, 1H), 8.35 (d, 1 H), 8.63 (br.s, 1H); HPLC- MS (Method A): m/z = 362 (M+H)+; Rt = 3.75 min.
Example 25
[Methyl-phenyl-carbamic acid 5-(3-bromo-benzoyIamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yI ester (122 mg, 0.5 mmol), 3-bromobenzoyl chloride (121 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 ml_) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (105 mg, 49% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ- 3.43 (br.s, 3H), 6.84 (br.s, 1H), 7.27 (m, 2H), 7.37 (m, 4H), 7.63 (d, 1 H), 7.83 (d, 1 H), 7.97 (br.s, 1 H), 8.05 (s, 1 H), 8.32 (s, 1 H), 8.90 (s, 1 H); HPLC-MS (Method A): m/z = 428 (M+H)+; Rt = 4.03 min.
Example 26
[Methyl-phenyl-carbamic acid 5-(3-cyano-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 3-cyanobenzoyl chloride (91 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (151 mg, 81% yield) as a white solid. 1H NMR (300 MHz, CDCI3): S= 3.45 (br.s, 3H), 6.80 + 6.95 (2 x br.s, 1H), 7.28 (m, 1 H), 7.39 (m, 4H), 7.52 (t, 1H), 7.80 (d, 1 H), 7.90 (br.s, 1 H), 8.18 (d, 1H), 8.28 (s, 1H), 8.32 (s, 1 H), 9.13 (s, 1 H); HPLC-MS (Method A): m/z = 373 (M+H)+; Rt = 3.52 min.
Example 27
[Methyl-phenyl-carbamic acid 5-(2-trifluoromethoxy-benzoylamino)-pyridin-2-yI ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 2-trifluoromethoxybenzoyl chloride (124 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (200 mg, 93% yield) as an oil, which solidified upon standing.
1H NMR (300 MHz, CDCI3): δ= 3.37 (br.s, 3H), 7.01 (br.s, 1 H), 7.26 (m, 1H), 7.28-7.44 (m, 6H), 7.54 (m, 1 H), 7.98 (dd, 1 H), 8.20 (dd, 1 H), 8.40 (s, 1 H), 8.60 (s, 1 H); HPLC-MS (Method A): m/z = 432 (M+H)+; Rt = 3.94 min. Example 28
[Methyl-phenyl-carbamic acid 5-(2-fIuoro-3-trifluoromethyl-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 2-fluoro-3(trifluoromethyl)benzoyl chloride (125 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 ml_) was stirred at room temperature for 1 hour. Dichloro- methane (3 ml_) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (150 mg, 69% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ- 3.37 (br.s, 3H), 7.00 (br.s, 1 H), 7.23 (m, 1H), 7.33 (m, 5H), 7.79 (t, 1 H), 8.18 (m, 2H), 8.40 (s, 1 H), 8.67 (d, 1H); HPLC-MS (Method A): m/z = 434 (M+H)+; Rt = 4.12 min.
Example 29
[Methyl-phenyl-carbamic acid 5-(3-trifluoromethyl-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 3-(trifluoromethyl)benzoyl chloride (115 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloro- methane (3 mL) was added to get a clear solution. The product was purified by flash column chromatography (SiO2), yielding the title compound (171 mg, 82% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 3.37 + 3.51 (2 x br.s, 3H), 6.80 + 6.95 (2 x br.s, 1 H), 7.18 - 7.46 (m, 5H), 7.53 (t, 1 H), 7.78 (d, 1 H), 8.00 (d, 1H), 8.11 (d, 1 H), 8.21 (s, 1 H), 8.30 (br.s, 1 H), 9.08 (s, 1H); HPLC-MS (Method A): m/z = 416 (M+H)+; Rt = 4.15 min.
Example 30
[Methyl-phenyl-carbamic acid 5-(3,4-difluoro-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (122 mg, 0.5 mmol), 3,4-difluorobenzoyl chloride (91 mg, 0.55 mmol) and triethylamine (56 mg, 0.55 mmol) in acetonitrile (2 mL) was stirred at room temperature for 1 hour. Dichloromethane (3 mL) was added to get a clear solution. The product was purified by flash column chromatog- raphy (SiO2), yielding the title compound (169 mg, 88% yield) as a white solid. 1H NMR (300 MHz, CDCI3): S= 3.43 (br.s, 3H), 6.81 (br.s, 1H), 7.15 (dd, 1H), 7.30 (m, 1 H), 7.39 (m, 4H), 7.68 (m, 1H), 7.82 (m, 2H), 8.30 (d, 1 H), 8.90 (br.s, 1 H); HPLC-MS (Method A): mlz = 384 (M+H)+; Rt = 3.47 min.
Example 31 [Methyl-phenyl-carbamic acid 5-(3-dimethyIamino-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (242 mg, 1.0 mmol), 3-dimethyIaminobenzoyl chloride hydrochloride (242 mg, 1.1 mmol) and triethylamine (0.31 ml_, 2.2 mmol) in dichloromethane (10 mL) was stirred at room temperature for 1 hour. The product was purified by flash column chromatography (SiO2, gradient of 0-15% ethyl acetate in dichloromethane) yielding the title compound (5.5 mg, 1% yield). 1H NMR (300 MHz, CDCI3): δ= 3.01 (s, 6H), 3.42 (br.s, 3H), 6.89 (dd, 1H), 7.02 (br.s, 1H), 7.10 (d, 1 H), 7.22-7.3 (m, 3H), 7.40 (m, 4H), 8.13 (br.s, 1H), 8.25 (dd, 1 H), 8.41 (br.s, 1 H); HPLC-MS (Method A): mlz = 391 (M+H)+; Rt = 2.94 min.
Example 32
[Methyl-phenyl-carbamic acid 5-(3-dimethylamino-benzoylamino)-pyridin-2-yl ester]
Phosgene (5 mL, 20% in toluene) was added to a stirred suspension of 6'-hydroxy- 4,4-dimethyl-4,5-dihydro-3/-/-[1 ,3']bipyridinyl-2,6-dione (0.47 g, 2.00 mmol) and triethylamine (0.29 mL, 2.00 mmol) in dichloromethane (10 mL). After stirring for 0.75 h at room temperature, the solvent and excess phosgene were evaporated under reduced pressure, yielding a white solid. The residue was dissolved in dichloromethane (10 mL) followed by the addition of 1 ,4-diazabicyclo[2.2.2]octane (224 mg, 2.00 mmol) and 2-methoxy-Λ/-methylaniline (0.27 g, 2.00 mmol) and stirring was continued for 0.75 hours at room temperature. The solution was extracted with water and evaporated in vacuo. The residue was purified by flash column chromatography (SiO2, gradient of 0-15% ethyl acetate in dichloromethane), yielding the title compound (260 mg, 33% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ = 1.19 (s, 6H), 2.66 (s, 4H), 3.29 + 3.40 (2 x s, 3H), 3.86 (s, 3H), 6.94 (m, 2H), 7.04-7.54 (m, 4H), 8.03 + 8.12 (d + s, 1 H); HPLC-MS (Method A): m/z = 398 (M+H)+; Rt = 3.62 min. Example 33
[Methyl-phenyl-carbamic acid 5-(4-nitro-benzoylamino)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.97 g, 4.00 mmol), 4-nitrobenzoyl chloride (0.78 g, 4.20 mmol) and triethylamine (0.59 ml_, 4.20 mmol) in dichloromethane (10 mL) was stirred at room temperature for 3 days. The solution was extracted with water and evaporated in vacuo. The residue was purified by flash column chromatography (SiO2, gradient of 40-80% ethyl acetate in heptane) yielding the title compound (1.51 g, 96% yield) as a white solid. 1H NMR (300 MHz, CDCI3): £3.42 + 3.53 (2 x br.s, 3H), 6.93 (br.s, 1H), 7.27-7.48 (m, 5H), 8.00 (d, 1 H), 8.03 (dd, 1 H + d, 2H), 8.20 (d, 2H), 8.38 (s, 1 H), 8.68 + 9.03 (2 x br.s, 1 H); HPLC-MS (Method A): m/z = 393 (M+H)+; Rt = 3.67 min.
Example 34
[Methyl-phenyl-carbamic acid 5-(4-amino-benzoylamino)-pyridin-2-yl ester]
A suspension of methyl-phenyl-carbamic acid 5-(4-nitro-benzoylamino)-pyridin-2-yl ester (1.50 g, 3.82 mmol) in ethyl acetate was hydrogenated in a Parr apparatus at 40 psi hydrogen pressure over night. The solution was filtered over a short pad of Celite and washed thoroughly with dichloromethane. The filtrate was evaporated in vacuo yielding the title compound (495 mg, 36% yield) as a slightly yellow solid.
1H NMR (300 MHz, DMSO-d6): δ= 3.33 (s, 3H), 5.80 (s, 2H), 6.60 (d, 2H), 7.17 (d, 1H), 7.29 (m, 1 H), 7.44 (m, 4H), 7.72 (d, 2H), 8.22 (dd, 1H), 8.62 (d, 1 H), 10.00 (s, 1 H); HPLC-MS (Method A): m/z = 363 (M+H)+; Rt = 2.83 min.
Example 35 [Methyl-phenyl-carbamic acid 5-(3-te/ϊ-butyl-ureido)-pyridin-2-yl ester]
A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (243 mg, 1.00 mmol) and terf-butylisocyanate (0.114 mL, 1.00 mmol) in dichloromethane (5 mL) was stirred at room temperature. The solvent was replaced by tetrahydrofuran and the solution was heated at 40 0C for 3 days. Evaporation of the solvent and purification of the residue by flash column chromatography (SiO2, gradient of 50-70% of ethyl acetate in heptane) yielded the title compound (119 mg, 35% yield) as a white solid.
1H NMR (300 MHz, CDCI3): £1.24 (s, 9H), 3.43 (br.s, 3H), 5.42 (br.s, 1 H), 6.85 (br.s, 1H), 7.26 (m, 1 H), 7.37 (m, 5H), 7.82 (br.s, 1 H), 7.89 (dd, 1 H); HPLC-MS (Method A): m/z = 343 (M+H)+; Rt = 3.31 min.
Example 36
[Methyl-phenyl-carbamic acid 5-(4-forrny!-benzoylamino)-pyridin-2-yl ester]
4-Formylbenzoyl chloride (1.56 g, 9.28 mmol) was added to a stirred solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (2.15 g, 8.84 mmol) and triethylamine (1.3 mL, 9.28 mmol). After 0.5 hours stirring at room temperature, the solvent was evaporated and the residue purified by flash column chromatography (SiO2, ethyl acetate/heptane 70/30), yielding the title compound (2.71 g, 82% yield).
1H NMR (300 MHz, CDCI3): £3.39 + 3.52 (2 x br.s, 3H), 6.87 (br.s, 1 H), 7.23-7.44 (m, 5H), 7.89 (d, 2H), 8.01 (m, 3H), 8.94 + 9.10 (2 x br.s, 1 H), 10.10 (s, 1 H); HPLC-MS (Method A): m/z = 476 (M+H)+; Rt = 3.36 min.
Example 37
[Methyl-phenyl-carbamic acid 5-(4-morpholin-4-ylmethyI-benzoylamino)-pyridin-2-yl ester]
Morpholine (0.144 mL, 1.65 mmol) was added to a stirred suspension of methyl- phenyl-carbamic acid 5-(4-formyl-benzoylamino)-pyridin-2-yl ester (0.56 g, 1.5 mmol) in methanol (15 mL). The solution was warmed carefully to get the starting material into solution. After stirring for 0.5 hours at room temperature sodium cyanoborohydride (104 mg, 1.65 mmol) was added and stirring was continued at room temperature overnight. The solvent was evaporated and the residue purified by flash column chromatography (SiO2), yielding the title compound (38 mg, 6% yield).
1H NMR (300 MHz, CDCI3): £2.45 (m, 4H), 3.41 (br.s, 3H), 3.53 (s, 2H), 3.71 (m, 4H), 6.91 (br.s, 1H), 7.27 (m, 1H), 7.38 (m, 6H), 7.84 (d, 2H), 8.09 (dd, 1 H), 8.38 (d, 1H), 8.75 (br.s, 1 H); HPLC-MS (Method A): m/z = 447 (M+H)+; Rt = 2.43 min. Example 38
[Methyl-phenyl-carbamic acid 5-(4-hydroxymethyl-benzoylamino)-pyridin-2-yl ester]
The title compound (16.4 mg, 2% yield) was isolated by flash column chromatogra- phy (SiO2) from the reaction mixture as described in Example 37.
1H NMR (300 MHz, DMSO-cfe): δ- 3.37 (br.s, 3H)1 4.61 (d, 2H), 5.35 (t, 1 H), 7.22 (d, 1H), 7.30 (m, 1 H), 7.40-7.51 (m, 6H), 7.97 (d, 2H), 8.27 (dd, 1 H), 8.68 (d, 1 H), 10.43 (s, 1H); HPLC-MS (Method A): mlz = 378 (M+H)+; Rt = 2.94 min.
Example 39 [Methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester]
A solution of 4-(chloromethyl)benzoyl chloride (8.39 g, 44.36 mmol) in dichloro- methane (50 mL) was added dropwise to a stirred solution of methyl-phenyl-carbamic acid 5- amino-pyridin-2-yl ester (10.79 g, 44.36 mmol) and triethylamine (6.2 mL, 44.36 mmol) in di- chloromethane (50 mL) with a some dimethylformamide. After stirring for 1 hour at room temperature, the solution was extracted with water, dried over sodium sulphate and evaporated in vacuo, yielding the title compound (14.8 g, 84% yield) as an off-white solid. 1H NMR (300 MHz, CDCI3): δ- 3.37 (br.s, 3H), 4.85 (s, 2H), 7.24 (d, 1 H), 7.30 (m, 1 H), 7.46 (m, 4H), 7.62 (d, 2H), 8.00 (d, 2H), 8.28 (dd, 1H), 8.69 (d, 1 H).; HPLC-MS (Method A): m/z = 396 (M+H)+; Rt = 3.83 min.
Example 40
[Methyl-phenyl-carbamic acid 5-(4-piperidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester]
Piperidine (0.17 g, 1.00 mmol) was added to a stirred solution of methyl-phenyl- carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in dimethylformamide (5 mL), followed by a catalytic amount of sodium iodide. After stirring for 18 hours at room temperature water was added slowly to the reaction mixture. The solid material was isolated by suction and dried in a vacuum oven, yielding the title compound (397 mg, 89% yield) as an off-white solid. 1H NMR (300 MHz, CDCI3): δ= 1.46 (m, 2H), 1.58 (m, 4H), 2.38 (m, 4H), 3.41 (br.s, 3H), 3.51 (S, 2H), 6.96 (br.s, 1 H), 7.27 (m, 1 H), 7.40 (m, 6H), 7.84 (d, 2H), 8.18 (dd, 1 H), 8.39 (d, 1H + br.s, 1 H); HPLC-MS (Method A): m/z = 445 (M+H)+; Rt = 2.57 min.
Example 41 [Methyl-phenyl-carbamic acid 5-[4-(4-methyl-piperidin-1-ylmethyl)-benzoylamino]-pyridin-2-yl ester]
4-Methylpiperidine (0.20 g, 1.00 mmol) was added to a stirred solution of methyl- phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in dimethylformamide (5 ml_), followed by a catalytic amount of sodium iodide. After stirring for 18 hours at room temperature, water was added slowly to the reaction mixture. The solid material was isolated by suction and dried in a vacuum oven, yielding the title compound (393 mg, 86% yield) as an off-white solid. 1H NMR (300 MHz, CDCI3): δ= 0.91 (d, 3H), 1.28 (m, 3H), 1.60 (m, 2H), 2.00 (m, 2H), 2.84 (m, 2H), 3.40 (br.s, 3H), 3.53 (s, 3H), 6.97 (br.s, 1 H), 7.27 (m, 1H), 7.39 (m, 6H), 7.85 (d,
2H), 8.20 (dd, 1H), 8.40 (d, 1H), 8.47 (br.s, 1H); HPLC-MS (Method A): m/z = 459 (M+H)+; Rt = 2. 74 min.
Example 42
[Methyl-phenyl-carbamic acid 5-[4-(2-ethyl-piperidin-1 -ylmethyl)-benzoylamino]-pyridin-2-yl ester]
2-Ethylpiperidine (0.23 g, 1.00 mmol) was added to a stirred solution of methyl- phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in dimethylformamide (5 mL), followed by a catalytic amount of sodium iodide. After stirring for 18 hours at room temperature, water was added slowly to the reaction mixture. The solvent was decanted and the residue was dried in a vacuum oven, yielding the title compound (430 mg, 91% yield) as an off-white solid.
1H NMR (300 MHz, CDCI3): δ= 0.92 (t, 3H), 1.32 (m, 1 H), 1.38-1.75 (m, 7H), 2.03 (m, 1 H), 2.27 (m, 1 H), 2.70 (m, 1H), 3.26 (d, 1 H), 3.41 (br.s, 3H), 4.02 (d, 1 H), 6.95 (br.s, 1 H), 7.26 (m, 1 H), 7.38 (m, 4H), 7.43 (d, 2H), 8.19 (dd, 1 H), 8.42 (d, 1 H), 8.62 (br.s, 1 H); HPLC-MS (Method A): m/z = 473 (M+H)+; Rt = 2. 77 min. Example 43
[Methyl-phenyl-carbamic acid 5-[4-(2-methyl-piperidin-1 -ylmethyl)-benzoylamino]-pyridin-2-yl ester]
2-Methylpiperidine (0.20 g, 1.00 mmol) was added to a stirred solution of methyl- phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in dimethylformamide (5 ml_), followed by a catalytic amount of sodium iodide. After stirring for 18 hours at room temperature, water was added slowly to the reaction mixture. The solid material was isolated by suction and dried in a vacuum oven, yielding the title compound (293 mg, 64% yield) as an off-white solid.
1H NMR (300 MHZi CDCI3): δ= 1.16 (d, 3H), 1.21-1.72 (m, 6H), 1.98 (m, 1H), 2.34 (m, 1H), 2.69 (m, 1H), 3.24 (d, 1 H), 3.45 (br.s, 3H), 4.04 (d, 1 H), 7.00 (br.s, 1 H), 7.27 (m, 1 H), 7.40 (m, 6H), 7.82 (d, 2H), 8.21 (dd, 1 H + br.s, 1H), 8.38 (d, 1H); HPLC-MS (Method A): m/z = 459 (M+H)+; Rt = 2. 64 min.
Example 44
[Methyl-phenyl-carbamic acid 5-[4-(3-methyl-piperidin-1 -ylmethyl)-benzoylamino]-pyridin-2-yl ester]
3-Methylpiperidine (0.20 g, 1.00 mmol) was added to a stirred solution of methyl- phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in dimethylformamide (5 ml_), followed by a catalytic amount of sodium iodide. After stirring for 18 hours at room temperature, water was added slowly to the reaction mixture. The solvent was decanted and the residue was dried in a vacuum oven, yielding the title compound (292 mg, 64% yield) as an off-white solid. 1H NMR (300 MHz, CDCI3): δ- 0.83 (d, 3H + m, 1H), 1.48-1.77 (m, 5H), 1.89 (dt, 1 H), 2.78 (m, 2H), 3.40 (br.s, 3H), 3.51 (s, 2H), 6.90 (br.s, 1 H), 7.27 (m, 1H), 7.38 (m, 6H), 7.85 (d, 2H), 8.10 (dd, 1 H), 8.38 (d, 1 H), 8.69 (br.s, 1 H).; HPLC-MS (Method A): m/z = 459 (M+H)+; Rt = 2. 71 min. Example 45
[Methyl-phenyl-carbamic acid 5-(4-dimethylaminomethyl-benzoylamino)-pyridin-2-yl ester]
Dimethylamine hydrochloride (82 mg, 1.00 mmol) and triethylamine (0.28 ml_, 2.00 mmol) were added to a stirred solution of methyl-phenyl-carbamic acid 5-(4-chloromethyl- benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in Λ/,Λ/-dimethylformamide (5 mL), followed by a catalytic amount of sodium iodide. The reaction mixture was stirred for 18 hours at room temperature. Water was added slowly and decanted. The residue was purified by preparative HPLC, yielding the title compound (165 mg, 32% yield) as the TFA-salt.
1H NMR (300 MHz, CDCI3): δ= 2.60 (s, 6H), 3.40 (br.s, 3H), 4.06 (s, 2H), 6.99 (br.s, 1 H), 7.18-7.42 (m, 7H), 7.82 (d, 2H), 8.19 (d, 1 H)1 8.54 (s, 1 H), 9.81 (br.s, 1H), 11.74 (br.s, 1H); HPLC-MS (Method A): m/z = 461 (M+H)+; Rt = 2.82 min.
Example 46
[Methyl-phenyl-carbamic acid 5-(4-diethylaminomethyl-benzoylamino)-pyridin-2-yl ester]
Diethylamine (0.15 g, 2.00 mmol) was added to a stirred solution of methyl-phenyl- carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) in N, N- dimethylformamide (5 mL), followed by a catalytic amount of sodium iodide. The reaction mixture was stirred for 18 hours at room temperature. Water was added slowly, the solid material was isolated by suction and dried in a vacuum oven, yielding the title compound (404 mg, 93% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ = 1.06 (t, 6H), 2.53 (q, 4H)1 3.42 (br.s, 3H)1 3.61 (s,
2H), 6.97 (br.s, 1 H)1 7.27 (m, 1 H), 7.39 (m, 4H)1 7.45 (d, 2H), 7.83 (d, 2H)1 8.18 (dd, 1H)1 8.38 (d, 1 H)1 8.42 (br.s, 1 H); HPLC-MS (Method A): m/z = 433 (M+H)+; Rt = 2.58 min.
Example 47
[Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester] Using the procedure as described in Example 46 and starting from pyrrolidine (0.14 g, 2.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) yielded the title compound (357 mg, 83% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ = 1.80 (m, 4H), 2.51 (m, 4H), 3.42 (br.s, 3H), 3.67 (s,
2H), 6.94 (br.s, 1 H), 7.27 (m, 1 H), 7.40 (m, 6H), 6.84 (d, 2H), 8.15 (dd, 1 H), 8.37 (d, 1H)1 8.52 (br.s, 1 H); HPLC-MS (Method A): m/z = 431 (M+H)+; Rt = 2.56 min. Example 48
[Methyl-phenyl-carbamic acid 5-(4-dipropylaminomethyl-benzoylamino)-pyridin-2-yl ester]
Using the procedure as described in Example 46 and starting from di-n-propylamine (0.20 g, 2.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyI-benzoylamino)- pyridin-2-yl ester (0.40 g, 1.00 mmol) yielded the title compound (402 mg, 87% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 0.88 (t, 6H), 1.48 (sextet, 4H), 2.37 (t, 4H), 3.42 (br.s, 3H), 3.60 (s, 2H), 6.94 (br.s, 1 H), 7.27 (m, 1H), 7.38 (m, 4H), 7.42 (d, 2H), 7.83 (d, 2H), 8.15 (dd, 1 H), 8.38 (d, 1H), 8.47 (br.s, 1H); HPLC-MS (Method A): m/z = 461 (M+H)+; Rt = 2.82 min.
Example 49
[Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester]
Using the procedure as described in Example 46 and starting from 4,4- dimethylpiperidine hydrochloride (0.22 g, 1.50 mmol), Λ/-ethyldiisopropylamine (0.52 ml_, 3.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) and stirring for 3 days yielded the title compound (341 mg, 72% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 0.92 (s, 6H), 1.40 (t, 4H), 2.40 (m, 4H), 3.40 (br.s, 3H), 3.54 (s, 2H), 6.94 (br.s, 1H), 7.27 (m, 1 H), 7.38 (m, 6H), 7.83 (d, 2H), 8.14 (dd, 1 H), 8.37 (d, 1 H), 8.54 (br.s, 1 H); HPLC-MS (Method A): mlz = 473 (M+H)+; Rt = 2.91 min.
Example 50
[c/s-Methyl-phenyl-carbamic acid 5-[4-(2,6-dimethyl-piperidin-1 -ylmethyl)-benzoylamino]- pyridin-2-yl ester]
Using the procedure as described in Example 46 and starting from c/s-2,6-dimethyl- piperidine (226 mg, 2.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl- benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) and stirring for 3 days yielded the title compound (410 mg, 87% yield).
1H NMR (300 MHz, CDCI3): δ= 1.00 (d, 6H), 1.32 (m, 3H), 1.51-1.70 (m, 3H)1 2.48
(m, 2H), 3.40 (br.s, 3H), 3.80 (s, 2H), 6.92 (br.s, 1H), 7.27 (m, 1H), 7.36 (m, 4H), 7.46 (d, 2H), 7.83 (d, 2H), 8.11 (dd, 1H), 8.40 (d, 1 H), 8.78 (br.s, 1H); HPLC-MS (Method A): m/z =
473 (M+H)+; Rt = 2.77 min. Example 51
[Methyl-phenyl-carbamic acid 5-[4-(4-oxo-piperidin-1 -ylmethyi)-benzoyIamino]-pyridin-2-yl ester]
Using the procedure as described in Example 46 and starting from 4-ketopiperidine hydrate hydrochloride (154 mg, 1.00 mmol), /V-ethyldiisopropylamine (259 mg, 2.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) and stirring for 2 days yielded the title compound (358 mg, 78% yield).
1H NMR (300 MHz, CDCI3): δ= 2.47 (m, 4H), 2.74 (m, 4H), 3.42 (br.s, 3H), 3.67 (s, 2H), 6.93 (br.s, 1H), 7.26 (m, 1 H), 7.38 (m, 4H), 7.42 (d, 2H), 7.87 (d, 2H), 8.12 (dd, 1H), 8.39 (d, 1 H), 8.66 (br.s, 1 H); HPLC-MS (Method A): m/z = 459 (M+H)+; Rt = 2.31 min.
Example 52
[c/s-Methyl-phenyl-carbamic acid 5-[4-(2,6-dimethyl-morpholin-4-ylmethyl)-benzoylamino]- pyridin-2-yl ester]
Using the procedure as described in Example 46 and starting from c/s-2,6-dimethyl- morpholine (230 mg, 2.00 mmol) and methyl-phenyl-carbamic acid 5-(4-chloromethyl- benzoylamino)-pyridin-2-yl ester (0.40 g, 1.00 mmol) yielded the title compound (300 mg, 63% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 1.12 (d, 6H), 1.77 (t, 2H), 2.66 (d, 2H), 3.38 (br.s, 3H), 3.50 (s, 2H), 3.70 (m, 2H), 6.89 (br.s, 1 H), 7.25 (m, 1H), 7.36 (m, 6H), 7.86 (d, 2H), 8.06 (dd, 1 H), 8.40 (d, 1 H), 9.03 (s, 1 H); HPLC-MS (Method A): m/z = 475 (M+H)+; Rt = 2.63 min.
Example 53
[Methyl-phenyl-carbamic acid 5-(4-thiomorpholin-4-ylmethyl-benzoylamino)-pyridin-2-yl ester]
Thiomorpholine (206 mg, 2.00 mmol) was added to a stirred solution of methyl- phenyl-carbamic acid 4-(4-chloromethyl-benzoylamino)-phenyl ester (396 mg, 1.00 mmol) and a catalytic amount of sodium iodide in dimethylformamide (5 mL). After stirring for 3 hours at room temperature, water was added to the reaction mixture and the precipitate was isolated by suction, washed thoroughly with water and dried in a vacuum oven at 40 0C, yielding the title compound (424 mg, 92% yield) as an off-white solid.
1H NMR (300 MHz, CDCI3): δ= 2.69 (m, 8H), 3.42 (br.s, 3H), 3.56 (s, 2H), 6.94 (br.s, 1 H), 7.27 (m, 1 H), 7.38 (m, 6H), 7.85 (d, 2H), 8.12 (dd, 1 H), 8.37 (d, 1H), 8.50 (s, 1 H); HPLC-MS (Method A): m/z = 463 (M+H)+; Rt = 2.61 min. Example 54
[Methyl-phenyi-carbamic acid 5-[3-(2-hydroxy-1,1-dimethyl-ethyl)-thioureido]-pyridin-2-yl ester]
Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.73 g, 3.00 mmol) was added to a solution of di-2-pyridyl thionocarbonate (0.70 g, 3.00 mmol) in dichloromethane (15 mL). After stirring for 2 hours 2-amino-2-methyl-1-propanol (0.27 g, 3.00 mmol), dissolved in a small amount of dichloromethane, was added in one portion. Stirring was continued overnight at room temperature. The product was purified by flash column chromatography (SiO2, gradient of 80-100% ethyl acetate in heptane). Crystallisation from ethyl ace- tate/heptane yielded the title compound (907 mg, 81 % yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 1.30 (s, 6H), 3.42 (br.s, 3H), 3.55 (s, 2H), 5.20 (br.s, 1 H), 6.41 (s, 1 H), 7.00 (br.s, 1 H), 7.27 (m, 1 H), 7.38 (m, 4H), 8.13 (s, 1H), 8.23 (br.s, 1H), 10.70 (br.s, 1H); HPLC-MS (Method A): m/z = 375 (M+H)+; Rt = 3.04 min.
Example 55 [Methyl-phenyl-carbamic acid 5-[3-(1 -methyl-cyclopropyl)-thioureido]-pyridin-2-yl ester]
Methyl-phenyl-carbamic acid 5-amino-pyridin-2~yl (243 mg, 1.00 mmol) was added to a solution of di-2-pyridyl thionocarbonate (232 mg, 1.00 mmol) in dichloromethane (5 mL).
The reaction mixture was stirred at room temperature for 2 hours. 1-Methylcyclopropylamine hydrochloride (113 mg, 1.05 mmol) was added in one portion, followed by triethylamine (146 μL, 1.05 mmol). Stirring was continued overnight at room temperature. Purification by flash column chromatography (SiO2, ethyl acetate/heptane 60/40) yielded the title compound (318 mg, 89% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ- 0.55-1.09 (3 x br.s, 4H), 1.43 (s, 3H), 3.44 (br.s, 3H),
7.04 (br.s, 2H), 7.28 (m, 1H), 7.39 (m, 4H), 7.73-8.38 (3 x br.s, 3H); HPLC-MS (Method A): m/z = 357 (M+H)+; Rt = 3.11 min.
Example 56
[Methyl-phenyl-carbamic acid 5-[3-(1-methyl-cyclobutyl)-thioureido]-pyridin-2-yl ester]
Using the procedure as described in Example 55 and starting from methyl-phenyl- carbamic acid 5-amino-pyridin-2-yl (243 mg, 1.00 mmol) and 1-methylcyclobutylamine hy- drochloride (128 mg, 1.05 mmol) yielded the title compound (261 mg, 71% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 1.59 (s, 3H), 1.81 (m, 2H), 2.02 (m, 2H), 2.16 (m, 2H), 3.32-3.60 (2 x br.s, 3H), 6.63-7.07 (4 x br.s, 2H), 7.28 (m, 1 H), 7.38 (m, 4H), 7.69-8.00 (2 x br.s, 3H); HPLC-MS (Method A): m/z = 371 (M+H)+; Rt = 3.68 min.
Example 57 [Methyl-phenyl-carbamic acid 5-(4-imidazol-1-yl-benzoylamino)-pyιϊdin-2-yl ester]
At 40 0C 1-hydroxybenzotriazole hydrate (0.75 g, 5.55 mmol) and 1-(3- dimethyIaminopropyl)-3-ethylcarbodiimide hydrochloride (1.06 g, 5.55 mmol) were added to a stirred solution of 4-imidazol-1-yl-benzoic acid (0.94 g, 5.00 mmol) in Λ/,Λ/-dimethylformamide (10 mL). After 30 minutes methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (1.35 g, 5.55 mmol) and Λ/-ethyldiisopropylamine (0.97 mL, 5.55 mmol) were added and stirring was continued overnight at 40 0C. The solvent was evaporated in vacuo, the crude product dissolved in 1 M aqueous HCI (100 mL) and extracted with ethyl acetate (2 x 100 mL). Sodium carbonate was slowly added to the water layer. The solids were isolated by suction and dried overnight in a vacuum oven yielding the title compound (1.00 g, 50% yield) as an off-white solid. —
1H NMR (400 MHz, DMSO-(Z6): δ= 7.17 (s, 1 H), 7.25 (d, 1 H), 7.30 (m, 1H), 7.46 (m, 4H), 7.89 (d, 2H), 7.91 (s, 1 H), 8.13 (d, 2H), 8.27 (dd, 1 H), 8.44 (s, 1H), 8.69 (d, 1 H), 10.58 (br.s, 1H); HPLC-MS (Method A): m/z = 414 (M+H)+; Rt = 2.40 min.
Example 58 [Methyl-phenyl-carbamic acid 5-(4-diethylamino-benzoylamino)-pyridin-2-yl ester]
At 40 0C 1-hydroxybenzotriazole hydrate (0.75 g, 5.55 mmol) and 1-(3- dimethylaminopropyI)-3-ethylcarbodiimide hydrochloride (1.06 g, 5.55 mmol) were added to a stirred solution of 4-diethylamine-benzoic acid (0.97 g, 5.00 mmol) in Λ/,Λ/-dimethylformamide (10 mL). After 30 minutes methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (1.35 g, 5.55 mmol) and Λ/-ethyldiisopropylamine (0.97 mL, 5.55 mmol) were added and stirring is continued overnight at 40 0C. The solvent was evaporated in vacuo. A small portion of the crude product (around 100 mg) was purified by preparative HPLC yielding the title compound (5 mg, 1% yield) as an off-white solid.
1H NMR (400 MHz, DMSO-d6): S= 1.12 (t, 6H), 3.42 (q, 4H), 6.73 (d, 2H), 7.18 (d, 1 H), 7.29 (m, 1 H), 7.45 (m, 4H), 7.87 (d, 2H), 8.24 (dd, 1 H), 8.65 (d, 1 H), 10.08 (s, 1 H); HPLC-MS (Method A): m/z = 419 (M+H)+; Rt = 3.20 min. Example 59
[Methyl-phenyl-carbamic acid 5-(4-[1 ,2,4]triazol-1-yl-benzoylamino)-pyridin-2-yl ester]
At 40 0C 1-hydroxybenzotriazole hydrate (0.13 g, 0.99 mmol) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.19 g, 0.99 mmol) were added to a stirred solution of 4-(1 /-/-1 ,2,4 triazol-1yl)benzoic acid (0.16 g, 0.82 mmol) in N,N- dimethylformamide (5 mL). After 30 minutes methyl-phenyl-carbamic acid 5-amino-pyridin-2- yl ester (0.20 g, 0.82 mmol) and Λ/-ethyldiisopropylamine (0.17 mL, 0.99 mmol) were added and stirring was continued overnight at 40 0C. The solvent was evaporated in vacuo. A small portion of the crude product (around 100 mg) was purified by preparative HPLC yielding the title compound (10 mg, 1 % yield) as a white solid.
1H NMR (400 MHz, DMSO-c/6): δ- 7.25 (d, 1 H), 7.30 (m, 1H), 7.45 (m, 4H), 8.07 (d, 2H), 8.18 (d, 2H), 8.28 (dd, 1H), 8.32 (s, 1 H), 8.69 (d, 1 H), 9.45 (s, 1 H), 10.62 (s, 1 H); HPLC- MS (Method A): m/z = 415 (M+H)+; Rt = 3.13 min.
Example 60 [Methyl-phenyl-carbamic acid 5-(3,3-dipropyl-thioureido)-pyridin-2-yI ester]
Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (2.92, 12.0 mmol), dissolved in Λ/,Λ/-dimethylformamide (20 mL), was added dropwise to a stirred solution of di-2-pyridyl thionocarbonate (2.79 g, 12.0 mmol) in Λ/,Λ/-dimethylformamide (15 mL). After stirring for 3 hours at room temperature, one-fourth of the solution (3.00 mmol) was added to di-n- propylamine (334 mg, 3.30 mmol), followed by the addition of triethylamine (0.46 mL). The reaction mixture was stirred at room temperature overnight. Purification by flash column chromatography (SiO2, ethyl acetate/heptane 50/50) yielded the title compound (252 mg, 22% yield) as a white solid.
1H NMR (300 MHz, CDCI3): S= 0.94 (t, 6H), 1.72 (sextet, 4H), 3.42 (br.s, 3H), 3.60 (t, 4H), 6.86 (br.s, 1 H), 7.26 (m, 1 H), 7.38 (m, 4H), 7.49 (br.s, 1 H), 7.72 (d, 1 H), 8.10 (d, 1 H); HPLC-MS (Method A): m/z = 387 (M+H)+; Rt = 4.07 min.
Example 61
[Methyl-phenyl-carbamic acid 5-(3,3-dibutyI-thioureido)-pyridin-2-yl ester]
Using the procedure as described in Example 60 and starting from methyl-phenyl- carbamic acid 5-amino-pyridin-2-yl ester (0.73 g, 3.00 mmol) and di-n-butylamine (427 mg, 3.30 mmol) yielded the title compound (283 mg, 23% yield) as a white solid. 1H NMR (300 MHz, CDCI3): δ= 0.97 (t, 6H), 1.38 (sextet, 4H), 1.68 (m, 4H), 3.43 (br.s, 3H), 3.66 (t, 4H), 6.93 (br.s, 1 H), 7.25 (m, 1H), 7.38 (m, 4H), 7.82 (d, 1H), 8.10 (d, 1H); HPLC-MS (Method A): m/z = 415 (M+H)+; Rt = 4.64 min.
Example 62 [Methyl-phenyl-carbamic acid 5-[(piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester]
Using the procedure as described in Example 60 and starting from methyl-phenyl- carbamic acid 5-amino-pyridin-2-yl ester (0.73 g 3.00 mmol) and piperidine (281 mg, 3.30 mmol), followed by flash column chromatography (SiO2, ethyl acetate/heptane 70/30) yielded the title compound (867 mg, 78% yield) as a white solid. 1H NMR (400 MHz, CDCI3): δ= 1.63 (m, 6H), 3.41 (br.s, 1 H), 3.82 (br.s, 4H), 6.83 +
6.91 (2 x br.s, 1 H), 7.27 (m, 1H), 7.37 (m, 4H), 7.60 (br.s, 1 H), 7.68 (br.s, 1H), 8.08 (br.s, 1H); HPLC-MS (Method A): m/z = 371 (M+H)+; Rt = 3.51 min.
Example 63
[Methyl-phenyl-carbamic acid 5-[(4-methyl-piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester] Using the procedure as described in Example 60 and starting from methyl-phenyl- carbamic acid 5-amino-pyridin-2-yl ester (0.73 g 3.00 mmol) and 4-methylpiperidine (281 mg, 3.30 mmol), followed by flash column chromatography (SiO2, ethyl acetate/heptane 60/40) yielded the title compound (0.94 g, 81% yield) as a white solid.
1H NMR (400 MHz, CDCI3): δ= 0.95 (d, 3H), 1.22 (m, 2H), 1.68 (m, 3H), 2.99 (t, 2H), 3.41 (br.s, 3H), 4.67 (d, 2H), 6.84 (br.s, 1 H), 7.28 (m, 1 H), 7.37 (m, 4H), 7.52-7.87 (3 x br.s, 2H), 8.19 (s, 1H); HPLC-MS (Method A): m/z = 385 (M+H)+; Rt = 3.85 min.
Example 64
[Methyl-phenyl-carbamic acid 5-[(4,4-dimethyl-piperidine-1 -carbothioyl)-amino]-pyridin-2-yI ester] Using the procedure as described in Example 60 and starting from methyl-phenyl- carbamic acid 5-amino-pyridin-2-yl ester (0.73 g 3.00 mmol), 4,4-dimethylpiperidine hydrochloride (494 mg, 3.30 mmol) and triethylamine (0.46 mL, 3.30 mmol) yielded the title compound (678 mg, 57% yield) as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.00 (s, 6H), 1.43 (m, 4H), 3.42 (br.s, 3H), 3.83 (m, 4H), 6.87 (br.s, 1H), 7.27 (m, 1 H), 7.38 (m, 4H), 7.53 (br.s, 1H), 7.62 (d, 1 H), 8.10 (s, 1 H); HPLC-MS (Method A): m/z = 399 (M+H)+; Rt = 4.06 min. Example 65
[(4-Bromo-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahyclro-2H- [1 ,3']bipyridinyl-6'-yl ester]
A solution of Λ/-(4-bromophenyl)-Λ/-methylcarbamoyl chloride (0.50 g, 2.00 mmol) in dichloromethane (5 ml.) was added to a stirred solution of 6'-hydroxy-4,4-dimethyl-4,5- dihydro-3H-[1 ,3']bipyridinyl-2,6-dione (0.47 g, 2.00 mmol) and 1 ,4-diazabicyclo[2.2.2]octane ,(0.22 g, 2.00 mmol) in Λ/,/V-dimethylformamide (10 ml_). After stirring for 4 hours at room temperature the solvent was evaporated in vacuo and the residue was purified by flash column chromatography (SiO2, ethyl acetate/heptane 60/40) yielding the title compound (176 mg, 20% yield) as a white solid.
1H NMR (300 MHz, CDCI3): δ= 1.20 (s, 6H), 2.68 (s, 4H), 3.43 (br.s, 3H), 7.16 (br.s, 1 H), 7.27 (d, 2H), 7.50 (m, 3H), 8.09 (d, 1 H); HPLC-MS (Method A): m/z = 446 + 448 (M+H)+; Rt = 3.88 min.
Example 66 [^-Chloro-phenyO-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 , 3'] bipyrid inyl-6'-yl ester]
Phosgene (20% in toluene, 45 ml_) was added slowly by means of a syringe to a stirred solution of6'-hydroxy-4,4-dimethyl-4,5-dihydro-3H-[1 ,3']bipyridinyl-2,6-dione (2.11 g, 9.00 mmol) and Λ/-ethyldiisopropylamine (1.62 ml_, 9.30 mmol) in dichloromethane (90 ml_). After stirring for 1.5 hours at room temperature the solvent was removed by evaporation in vacuo and the residue was redissolved in dichloromethane (45 ml_). One ninth of this solution was added to a mixture of (4-chlorophenyl)methylamine (156 mg, 1.10 mmol) and 1 ,4- diazabicyclo[2.2.2]octane (112 mg, 1.00 mmol) in dichloromethane (2 ml_). After standing overnight the solution was extracted twice with water. The dichloromethane layer was evapo- rated and the residue was purified by preparative HPLC yielding the title compound (103 mg, 26% yield) as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.20 (s, 6H), 2.69 (s, 4H), 3.41 (br.s, 3H), 7.14 (br.s, 1H), 7.33 (m, 4H), 7.50 (br.d, 1H), 8.09 (br.s, 1H); HPLC-MS (Method A): m/z = 402 (M+H)+; Rt = 3.82 min. Example 67
[(3>4-Dichloro-phenyl)-methyl-carbamic acid 4)4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1 ,3']bipyridinyI-6'-yl ester]
Using the procedure as described in Example 66 and starting from (3,4- dichlorophenyl)methylamine (194 mg, 1.10 mmol) yielded the title compound (53 mg, 12% yield) as a white solid.
1H NMR (400 MHz, CDCI3): J= 1.20 (s, 6H), 2.69 (s, 4H), 3.43 (br.s, 3H), 7.19 (br.s, 1H), 7.27 (m, 1 H), 7.45 (d, 1H), 7.51 (m, 1 H), 8.10 (br.s, 1 H); HPLC-MS (Method A): m/z = 436 (M+H)+; Rt = 4.16 min.
Example 68
[(3-Chloro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1,3']bipyridinyI-6'-yl ester]
Using the procedure as described in Example 66 and starting from (3- chlorophenyl)methylamine (156 mg, 1.10 mmol) yielded the title compound (107 mg, 27% yield) as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.20 (s, 6H), 2.69 (s, 4H), 3.44 (br.s, 3H), 7.19 (br.s, 1 H), 7.29 (m, 3H), 7.40 (s, 1 H), 7.50 (d, 1 H), 8.10 (s, 1 H); HPLC-MS (Method A): m/z = 402 (MH-H)+; Rt = 3.82 min.
Example 69 [Methyl-p-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H-[1 ,3']bipyridinyl-6'- yl ester]
Using the procedure as described in Example 66 and starting from (4- methylphenyl)methylamine (133 mg, 1.10 mmol) yielded the title compound (118 mg, 31% yield) as a white solid. 1H NMR (400 MHz, CDCI3): δ= 1.20 (s, 6H), 2.34 (s, 3H), 2.68 (s, 4H), 3.39 (br.s,
3H), 7.11 (br.s, 1 H), 7.18 (d, 2H), 7.25 (d, 2H), 7.46 (br.d, 1H), 8.08 (br.s, 1H); HPLC-MS
(Method A): m/z = 382 (M+H)+; Rt = 3.71 min. Example 70
[(3-Fluoro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- ester]
Using the procedure as described in Example 66 and starting from (3-fluorophenyl)- methylamine (138 mg, 1.10 mmol) yielded the title compound (60 mg, 16% yield) as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.20 (s, 6H), 2.69 (s, 4H), 3.45 (br.s, 3H), 6.98 (dt, 1H), 7.12 (br.d, 1 H), 7.19 (d, 1 H), 7.34 (m, 1 H), 7.50 (d, 1H), 8.10 (s, 1 H); HPLC-MS (Method A): m/z = 386 (M+H)+; Rt = 3.56 min.
Example 71
[Methyl-m-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H-[1 ,3']bipyridinyl- 6'-yl ester]
Using the procedure as described in Example 66 and starting from (3- rnethylphenyl)methylamine (133 mg, 1.10 mmol) yielded the title compound (100 mg, 26% yield) as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.20 (s, 6H), 2.37 (s, 3H), 2.68 (s, 4H), 3.40 (br.s, 3H), 7.07 (d, 1H), 7.15 (m, 3H), 7.27 (t, 1H), 7.48 (br.d, 1H), 8.09 (br.s, 1H); HPLC-MS (Method A): m/z = 382 (M+H)+; Rt = 3.72 min.
Example 72
[(4-Methoxy-phenyl)-methyI-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester]
By means of syringe phosgene (20% in toluene, 5 mL) was slowly added to a solution of 6'-hydroxy-4,4-dimethyl-4,5-dihydro-3/-/-[1 ,3']bipyridinyl-2,6-dione (333 mg, 1.42 mmol) and /V-ethyldiisopropylamine (0.14 g, 1.10 mmol) in dichloromethane (15 mL). After stirring for 0.5 hours at room temperature the solvent and excess of phosgene were removed by evaporation in vacuo. The residue was redissolved in dichloromethane. The solution was slowly added to a cold solution of (4-methoxyphenyl)methylamine (151 mg, 1.10 mmol) and 1 ,4-diazabicyclo[2.2.2]octane (0.11 mmol, 1.00 mmol) in dichloromethane (4 mL). After stir- ring overnight the solution was extracted twice with water and evaporated in vacuo. The residue was purified by preparative HPLC. Crystallisation from ethyl acetate yielded the title compound (10 mg, 3% yield) as a white solid. 1H NMR (400 MHz, CDCI3): δ= 1.21 (s, 6H), 2.68 (s, 4H), 3.37 + 3.49 (2 x br.s, 3H), 3.81 (s, 3H), 6.90 (d, 2H), 7.10 (br.d, 1H)1 7.26 (m, 3H), 7.45 (br.d, 1H), 8.06 (br.s, 1H); HPLC-MS (Method A): m/z = 398 (M+H)+; Rt = 3.20 min.
Example 73 [(3-Methoxy-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester]
Using the procedure as described in Example 72 and starting from 6'-hydroxy-4,4- dimethyl-4,5-dihydro-3H-[1 ,3']bipyridinyl-2,6-dione (333 mg, 1.42 mmol) and (3- methoxyphenyl)methylamine (151 mg, 1.10 mmol) yielded the title compound as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.21 (s, 6H), 2.69 (s, 4H), 3.43 (br.s, 3H), 3.81 (s, 3H), 6.82 (d, 1H), 6.95 (m, 2H), 7.14 (br.s, 1 H), 7.30 (d, 1 H), 7.48 (br.d, 1 H), 8.09 (br.s, 1 H); HPLC-MS (Method A): m/z = 398 (M+H)+; Rt = 3.14 min.
Example 74 [Methyl-(3-trifluoromethyl-phenyl)-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2H-[1 ,3']bipyridinyl-6'-yl ester]
Using the procedure as described in Example 72 and starting from 6'-hydroxy-4,4- dimethyl-4,5-dihydro-3H-[1,3']bipyridinyl-2,6-dione (333 mg, 1.42 mmol) and (3- trifluoromethylphenyl)methylamine (193 mg, 1.10 mmol) yielded the title compound as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.19 (s, 6H), 2.67 (s, 4H), 3.48 (br.s, 3H)1 7.19 (br.s, 1 H), 7.52 (m, 3H), 7.60 (s, 1H), 7.65 (s, 1 H), 8.10 (s, 1H); HPLC-MS (Method A): m!z = 436 (M+H)+; Rt = 3.71 min.
Example 75 [(3-Bromo-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H-
[1 , 3'] bi py rid i ny l-6'-y I ester]
Using the procedure as described in Example 72 and starting from 6'-hydroxy-4,4- (333 mg, 1.42 mmol) and (3- bromophenyl)methylamine (205 mg, 1.10 mmol) yielded the title compound as a white solid. 1H NMR (400 MHz, CDCI3): J= 1.21 (s, 6H), 2.68 (s, 4H), 3.44 (br.s, 3H), 7.05-7.60 (m, 6H),
8.10 (s, 1 H); HPLC-MS (Method A): m/z = 446 + 448 (M+H)+; Rt = 3.61 min. Example 76
[(4-Fluoro-phenyl)-methyl-carbarnic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester]
Using the procedure as described in Example 72 and starting from 6'-hydroxy-4,4- dimethyl-4,5-dihydro-3H-[1 ,3']bipyridinyl-2,6-dione (333 mg, 1.42 mmol) and (4-fIuorophenyl)- methylamine (138 mg, 1.10 mmol) yielded the title compound as a white solid. 1H NMR (400 MHz, CDCI3): S= 1.20 (s, 6H), 2.68 (s, 4H), 3.38 + 3.50 (2 x br.s, 3H), 7.07 (m, 3H), 7.33 (m, 2H), 7.48 (br.s, 1 H), 8.08 (s, 1 H); HPLC-MS (Method A): m/z = 386 (M+H)+; Rt , = 3.48 min.
Example 77
[[4-(2-Hydroxy-ethyl)-phenyl]-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2H-[1.S'lbipyridinyl-β'-yl ester]
Step A: A solution of 4-aminophenethylalcohol (2.03 g, 14.8 mmol) in ethyl formate (15 mL) was heated at reflux overnight. After cooling to room temperature heptane was added to the reaction mixture. The solvent was decanted from the oil and the last traces of solvent were removed in vacuo. Dichloromethane was added to the residue and the precipitate was isolated by suction, yielding Λ/-[4-(2-hydroxyethyl)-phenyl]-formamide (1.95 g, 80% yield), which was used without further purification in the next step
1H NMR (400 MHz, CDCI3): S= 2.04 (br.s, 1 H), 2.83 (m, 1 H), 3.84 (m, 2H), 7.02 + 7.46 (2 x d, 2H), 7.18 + 7.22 (2 x d, 2H), 7.62 + 8.22 (br.s + br.d, 1H), 8.27 + 8.60 (s + d, 1H); HPLC-MS (Method A): m/z = 148 (M-OH)+; Rt = 1.00 min.
Step B: Under a nitrogen atmosphere, a solution of Λ/-[4-(2-hydroxyethyl)-phenyl]-formamide
(1.50 g, 9.10 mmol) in dry tetrahydrofuran (50 mL) was added dropwise to a stirred suspension of lithium aluminium hydride (0.76 g, 20.0 mmol) in dry tetrahydrofuran (50 mL). After refluxing for 1 hour, the solution was cooled to room temperature and 1M aqueous potassium hydroxide (1.9 mL) was slowly added. Celite was added and the solids are removed by filtra- tion. Evaporation of the solvent in vacuo yielded 2-(4-methylamino-phenyl)-ethanol (1.00 g, yield: 73%), which was used in the next step without further purification.
1H NMR (400 MHz, CDCI3): S= 2.76 (t, 2H), 2.82 (s, 3H), 3.79 (t, 2H), 6.58 (d, 2H), 7.05 (d, 2H); HPLC-MS (Method A): m/z = 152 (M+H)+; Rt = 0.88 min. Step C:
Λ/-Ethyldiisopropylamine (0.7 mL, 4.00 mmol) and chlorotrimethylsilane (0.13 mL, 1.00 mmol) are added to a stirred solution of 2-(4-methylamino-phenyl)-ethanol (151 mg, 1.00 mmol) in dichloromethane (10 mL). In a second reaction flask Λ/-ethyldiisopropylamine (0.21 mL, 1.20 mmol) and phosgene (20% in toluene, 5 mL) are added to a stirred solution of δ'-hydroxy^^-dimethyl^.δ-dihydro-SH-ti .S'lbipyridinyl-a.θ-dione (234 mg, 1.00 mmol) in dichloromethane (5 mL). After 1.5 hours this solution is evaporated in vacuo. The residue is redissolved in dichloromethane (5 mL) and slowly added to the first solution. After stirring for 1 hour the solvent is evaporated in vacuo and the residue is purified by preparative HPLC yielding the title compound as a white solid.
1H NMR (400 MHz, CDCI3): δ= 1.20 (s, 6H), 1.92 (br.s, 1 H), 2.68 (s, 4H), 2.86 (t, 2H), 3.40 (br.s, 3H), 3.85 (t, 2H), 7.12 (br.s, 1 H), 7.20-7.34 (m,4H), 7.48 (br.s, 1 H), 8.07 (s, 1 H); HPLC-MS (Method A): m/z = 412 (M+H)+; Rt = 2.56 min.
Further examples are :
Methyl-phenyl-carbamic acid 5-(4-piperidin-1-yl-benzoylamino)-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-[4-(2-methyl-piperidin-1-yl)-benzoylamino]-pyridin-2- yl ester
Methyl-phenyl-carbamic acid 5-[4-(3-methyl-piperidin-1 -yl)-benzoylamino]-pyridin-2- yl ester
Methyl-phenyl-carbamic acid 5-[4-(4-methyl-piperidin-1-yl)-benzoylamino]-pyridin-2- yl ester
Methyl-phenyl-carbamic acid 4-[4-(2-ethyl-piperidin-1-yl)-benzoyIamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(4,4-dimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester Methyl-phenyl-carbamic acid 4-[4-(2,6-dimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,4,6-trimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,6-dimethyl-piperidin-1 -ylmethyl)-benzoyiamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(4,4-dimethyl-piperidin-1 -ylmethyl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,4,6-trimethyl-piperidin-1 -ylmethyl)- benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-[4-(2-piperidin-1 -yl-ethyl)-benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2-methyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(3-methyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(4-methyl-piperidin-1-yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2-ethyl-piperidin-1-yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(4,4-dimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2,6-dimethyl-piperidin-1-yl)-ethyl]- benzoylamino}-pyridin-2-yl ester Methyl-phenyl-carbamic acid 5-{4-[2-(2,4,6-trimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yl ester
PHARMACOLOGICAL METHODS
Compounds of formula I may be evaluated in vitro for their efficacy and potency to inhibit HSL, and such evaluation may be performed as described below.
ASSAYS
Hormone-sensitive lipase (HSL)
Materials. The Hormone-sensitive lipase was provided by Dr. Cecilia Holm, from Lund University Sweden or produced and purified by Novo Nordisk (NN) using the reagents and protocols used by Dr. Holm. The substrates used are: 3H-Iabeled triolein (TO) from Amersham, Buckinghamshire, U.K. cat No. TRA191 ; 5-20 Ci/mmol dissolved in toluene, triolein (Sigma, Cat. No. T-1740), fluorochrome-labeled triacylglyceride (c/s-octadec-9-enoic acid 2-[12-(7- nitrobenzo[1 ,2,5]oxadiazol-4-ylamino)dodecanoyloxy]-1 -c/s-octadec-9-enoyloxymethyl-ethyl ester) prepared by Novo Nordisk (NN) by conventional methods, and 1 ,3-(di[3H]-stearin), 2- (PEG-Biotin)glycerol prepared in collaboration with Amersham Pharmacia Biotech, UK and described in WO 01/073442. Phosphatidyl choline (PC) and phosphatidyl inositol (Pl) are from Sigma (St Luis MO cat. Nos. P-3556 and P-5954 respectively). All other reagents are of commercial grade and obtained from various commercial sources.
Methods.
3190.1: Assay for determination of percent inhibition of hormone sensitive lipase by com- pound at 10μM sample concentration.
A lipid emulsion with fluorochrome-labeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12μg/mL initial concentration corresponding to 600ng/mL final concentration). BSA is added as product acceptor. The transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluo- rescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm.
Compound and HSL (20μL compound, 10μl_ enzyme and 70μL PED-BSA buffer) is pre-incubated for 30min at 250C before addition of substrate (100μl_). Amount of formed product is measured after 120min incubation at 370C.
Results are given as percent activity relative to a non-inhibited sample (no compound).
3190.2: Assay for determination of IC50 value for the inhibition of hormone sensitive lipase by compound. Standard concentrations of compound are 100//M and 5-fold dilutions (initial concentration corresponding to 10//M final concentration and 5-fold).
A lipid emulsion with fluorochrome-iabeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12μg/mL initial concentration corresponding to 600ng/mL final concentration). BSA is added as product acceptor. The transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluorescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm.
Compound and HSL (20μL compound, 10μL enzyme and 70μL PED-BSA buffer) is pre-incubated for 30min at 250C before addition of substrate (1 OOμL). Amount of formed product is measured after 120min incubation at 370C.
Results are given as IC50 values after 4PL fit of obtained activity data.
RESULTS
With these methods the compounds of the examples are found to be inhibitors of
HSL :
Table 1. Inhibition of HSL by compounds of the examples according to above assay 3190.1 (% activity relative to non-inhibited sample).

Claims

1. A compound of the general formula (I) :
wherein
R1 and R2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, amide, urea, thiourea, benzamide, thioamide, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, het- eroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, amide, urea, thiourea, benzamide, thioamide, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, het- eroaryl, C3^-heterocyclyl and C3-10-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, thioxo, halogen, amino, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10- cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-aIkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C^o-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, d-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C^o-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyI, aryl, heteroaryl, C3-8- heterocyclyl and C3-i0-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C1-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not 2,2-Dimethyl-Λ/-[6-(methyl-phenyI-carbamoyloxy)-pyridin-3-yl]-succinamic acid,3,3-DimethyI- 4-[6-(methyl-phenyl-carbamoyioxy)-pyridin-3-ylcarbamoyl]-butyric acid, Methyl-phenyl- carbamic acid pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid S-chloro-S-trifluoromethyl-pyridin^-yl ester, Methyl-phenyl-carbamic acid 5- benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(cyclohexanecarbonyl- amino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl- propionylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2-cyclohexyl- acetylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-butyrylamino)- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(pyridine-2-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(6-chloro-pyridine-3-carbonyl)-amino]-pyridin-2-yl es- ter, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 2,6-dioxo-3>4,5,6-tetrahydro-2H-[1,3I]bipyridinyl-6'-yl ester, Methyl- phenyl-carbamic acid 5-(2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yI ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chIoro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yI ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-benzenesulfonyIamino-pyridin-2-yI ester, Methyl- phenyl-carbamic acid 5-(3,3-dimethyl-2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-[3,3-dimethyl-5-(4-methyl-piperazin-1 -yI)-5-oxo-pentanoyIamino]- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[3,3-dimethyl-4-(pyridin-3-ylcarbamoyl)- butyrylamino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-5-morpholin-4- yl-5-oxo-pentanoylamino)-pyridin-2-yI ester, Methyl-phenyl-carbamic acid 5-[4-(2- dimethylamino-ethylcarbamoyl)-3,3-dimethyl-butyrylamino]-pyridin-2-yl ester; N-Methyl-N- phenylcarbamic acid 5-nitro-3-trifluoromethylpyridin-2-yl ester, N-Methyl-N-phenylcarbamic acid 3-nitropyridin-2-yl ester, and N-Methyl-N-phenylcarbamic acid 5-n itropyri d i n-2-y I ester
as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
2. A compound according to claim 1 , wherein R2 is selected from hydrogen, hydroxy, amino, halogen, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, amide, urea and thiourea and C3-10-CyClOaIKyI, wherein each of hydroxy, amino, C1-6-alkyl, C1-6-alkoxy, C2- 6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, amide, urea and thiourea and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, d-β-alkyl, d-6-alkoxy, C2-6-aIkenyl, aryl, het- eroaryl, C3-8-heterocyclyl, and C3-10-CyClOaIRyI.
3. A compound according to claim 2, wherein R2 is halogen or hydrogen.
4. A compound according to any one of claims 1-3, wherein R4 is selected from hydrogen, halogen, C1-6-alkyl, C2-6-alkenyl, wherein each of C^-alkyl, C2-6-alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-β-heterocyclyl and Ca^o-cycloalkyl.
5. A compound according to claim 4, wherein R4 is selected from hydrogen, halogen and C1- 6-alkyl.
6. A compound according to claim 5, wherein R4 is hydrogen.
7. A compound according to claim 5, wherein R4 is halogen.
8. A compound according to any one of claims 1-7, wherein R3 is selected from hydrogen, hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, wherein each of hydroxy, Ci-6-alkyl, C2-6-alkenyl is optionally substituted with one or more substituents independently selected from hydroxy, halogen, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl.
9. A compound according to claim 8, wherein R3 is selected from halogen, C1-6-alkyl, meth- oxy, perhalomethyl and perhalomethoxy.
10. A compound according to claim 9, wherein R3 is selected from halogen, methyl, ethyl, isopropyl, methoxy and perhalomethyl.
11. A compound according to claim 10, wherein R3 is selected from halogen, methyl, methoxy and perhalomethyl.
12. A compound of the general formula (I) : wherein
R1 and R2 are independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C1-6-alkyl, Ci-6-aIkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10- cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and Cs-iQ-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, Ci-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-i0-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C2-6-alkenyl, aryl, heteroaryl, C^a-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, Ci-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C1-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not
2,2-Dimethyl-Λ/-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-yl]-succinamic acid,3,3-Dimethyl- 4-[6-(methyl-phenyI-carbamoyloxy)-pyridin-3-ylcarbamoyl]-butyric acid, Methyl-phenyl- carbamic acid pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-trifluoromethyl-pyridin-2-yl ester, Methyl-phenyl-carbamic acid S-chloro-δ-trifluoromethyl-pyridin^-yl ester, Methyl-phenyl-carbamic acid 5- benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(cyclohexanecarbonyl- amino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6- tetrahydro-2H-[1.S^bipyridinyl-θ'-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyI- propionylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2-cycIohexyl- acetylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-butyrylamino)- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(pyridine-2-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(6-chloro-pyridine-3-carbonyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 2,6-dioxo-3,4,5,6-tetrahydro-2H-[1 ,3']bipyridinyI-6'-yl ester, Methyl- phenyl-carbamic acid 5-(2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 4,4-dimethyl-3,4,5,6- tetrahydro-2H-[1 ,3']bipyridinyl-6'-yl ester, Methyl-phenyl-carbamic acid 5-aminc~pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-benzenesulfonylamino-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-(3,3-dimethyl-2,5-dioxo-pyrrolidin-1-yl)-pyridin-2-yl ester, Methyl- phenyl-carbamic acid 5-[3,3-dimethyl-5-(4-methyl-piperazin-1-yl)-5-oxo-pentanoylamino]- pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[3,3-dimethyl-4-(pyridin-3-ylcarbamoyl)- butyrylamino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(3,3-dimethyl-5-morpholin-4- yl-5-oxo-pentanoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[4-(2- dimethylamino-ethyIcarbamoyl)-3,3-dimethyl-butyrylamino]-pyridin-2-yl ester; as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
13. A compound of the general formula (I) :
(D wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and C3-10-CyClOaIkYl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl and C3-10-cycIoalkyI may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyI, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, Ci-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C^-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyI, C2-6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C1-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
14. A compound of the general formula (I) : wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-CyClOaIRyI, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyI, C1-6-alkoxy, C2-6-alkenyl, aryl, het- eroaryl, C3-8-heterocyclyI and C3-1o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6- alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl;
R3, and R4 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C^o-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, Ci-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, C1-6-alkyl, perhalomethyl and perhalomethoxy;
with the proviso that said compound is not Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyI-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-y! ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
15. A compound of the general formula (I) :
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-CyClOaIKyI, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl and C3.1o-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6- alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-10-cycloalkyl;
R3, and R4 are hydrogen with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
16. A compound of the general formula (I) :
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, sulfanyl, amino, halogen, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^e-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, Ci-6- alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3.8- heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, Ci-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^s-heterocyclyl, and C3-io-cycloalkyl;
R3, and R4 are hydrogen with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
17. A compound of the general formula (I) :
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, amino, halogen, d-6-alkyl, C1-6- alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of hydroxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10- cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-10-cycloalkyl,
R3 and R4 are hydrogen
with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyI-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
18. A compound of the general formula (I) :
wherein
R2 is H and R1 is
each R5 is independently selected from hydrogen, hydroxy, amino, halogen, C1-6-alkyl, C1-6- alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-I0-CyClOaIkVl, wherein each of hydroxy, amino, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl and C3- 1o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10-cycloalkyl,
R3 and R4 are hydrogen
with the proviso that said compound is not
Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-trifluoromethyl-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4- chloro-benzoylamino)-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-(4-methoxy- benzoylamino)-pyridin-2-yl ester, as well as diastereomers, enantiomers or tautomeric forms thereof including mixtures of these, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, or polymorphs.
19. A compound according to any one of claims 1-18, wherein R2 is selected from from hydrogen, hydroxy, amino, halogen, C1-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl and Cs^o-cycloalkyl, wherein each of hydroxy, Ci-6-alkyl, C1-6-alkoxy, C2-6- alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-CyClOaIk^ may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C^-heterocycIyl, and C3-i0- cycloalkyl.
20. A compound according to any one of claims 1-19, wherein R3 is selected from fluor, chlor, methyl, methoxy, perhalomethyl or perhalomethoxy.
21. A compound according to claim 12, wherein R2 is hydrogen.
22. A compound according to claim 12, wherein R2 is selected from the group consisting of
f SΛϊCCHH3: CH
23. A compound according to any of claims 1 and 12, wherein R2 is selected from the group consisting of where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Ca-β-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, Ci-6-alkyl, Ci-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl;
24. A compound according to any of claims 1 and 12, wherein R2 is selected from the group consisting of
* where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-10-cycloalkyl;
25. A compound according to claim 12, wherein R2 is selected from the group consisting of
26. A compound according to claim 12, wherein R2 is selected from the group consisting of H H ♦ C\H3 ψ*
VS-CH; / VS_CH2 NVS.CH . L .S^CH;
VN ' VN - VVRNl 2 aanndd V 1 "
27. A compound according to claim 12, wherein R 22 is selected from the group consisting of
28. A compound according to any one of claims 1 and 12-20, wherein R1 is selected from the group consisting of
29. A compound according to any one of claims 1, 12 and 28, wherein R1 is selected from the group consisting of
30. A compound according to any one of claims 1 , 12 and 28, wherein R1 is selected from the group consisting of
31. A compound according to any one of claims 1, 12 and 28, wherein R1 is selected from the group consisting of
32. A compound according to any of claims 1 and 12, wherein R1 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and Ca^o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more sub- stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perha- lomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and Cs-io-cycloalkyl;
33. A compound according to any of claims 1 and 12, wherein R1 is selected from the group consisting of
where each Rx is independently selected from hydroxy, sulfanyl, oxo, halogen, amino, sulfo, perhalomethyl, perhalomethoxy, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8- heterocyclyl, and C3-1o-cycloalkyl;
34. A compound according to any of claims 1 and 12, wherein R1 is selected from the group consisting of where each Rx is independently selected from halogen, perhalomethyl, perhalomethoxy, C1- 6-alkyl, heteroaryl, Ca-s-heterocyclyl, and C3-10-cycloalkyl;
35. A compound according to any one of claims 1-34, wherein R3 is hydrogen.
36. A compound according to any one of claims 1-35, wherein R4 is hydrogen.
37. A compound according to any one of claims 1-35, wherein R4 is selected from fluor, chlor, methyl, perhalomethyl or perhalomethoxy.
38. A compound according to any one of claims 1-37, having one free -COOH group.
39. A compound according to any one of claims 1-38, having one free amino group, or one monosubstituted amino group or one disubstituted amino group.
40. A compound according to any one of claims 1-39, having one substituted or unsubsti- tuted pyridine ring.
41. A compound according to any one of claims 1-40, having one substituted or unsubsti- tuted imidazole ring.
42. A compound according to any one of claims 1-41 , wherein the molar weight of said com- pound is less than 650 g/mole.
43. A compound according to any one of claims 1-42, wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 6.0.
44. A compound according to any one of claims 1-42, wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 5.0.
45. A compound according to any one of claims 1-42, wherein the compound contains no ionisable group and wherein cLog P is in the range from 1.0 to 4.0.
46. A compound according to any one of claims 1-45, wherein the compound contains no ionisable group and wherein cLog P is in the range from 2.0 to 4.0.
47. A compound according to any one of claims 1-46, wherein the ACD LogD is in the range from 0.8 to 3.0.
48. A compound according to any one of claims 1-47, wherein the number of H-bond donors is 0, 1 , 2 or 3.
49. A compound according to any one of claims 1-48, wherein the number of H-bond donors is O, 1 , or 2.
50. A compound according to any one of claims 1-49, wherein the number of H-bond acceptors is in the range from 4 to 9.
51. A compound according to any one of claims 1-50, wherein the number of H-bond accep- tors is in the range from 6 to 8.
52. A compound according to any one of claims 1-51 , wherein the number of rotatable bonds of said compound is in the range from 4 to 14.
53. A compound according to any one of claims 1-52, wherein the number of rotatable bonds of said compound is in the range from 8 to 12.
54. A compound according to any one of claims 1-53, wherein the polar surface area (PSA) is in the range from 50 A2 to120 A2.
55. A compound according to any one of claims 1-54, wherein the polar surface area (PSA) is in the range from 60 A2 to100 A2.
56. A compound according to any one of the preceeding claims, where the compound is se- lected from the group consisting of [Methyl-phenyl-carbamic acid 5-[2-(4,4-dimethyl-2,6-dioxo-piperidin-1 -y l)-ethy l]-py ri d i n-2-y I ester],[[6-(MethyI-phenyl-carbamoyloxy)-pyridin-3-ylamino]-acetic acid ferf-butyl ester],
[[6-(Methyl-phenyI-carbamoyloxy)-pyridin-3-ylamino]-acetic acid],
[Methyl-phenyl-carbamic acid 5-isothiocyanato-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester],
[[6-(Methyl-phenyl-carbamoyloxy)-pyridin-3-ylamino]-acetic acid methyl ester],
[Methyl-phenyl-carbamic acid 5-(4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-ethyl-5-oxo-2-thioxo-imidazoIidin-1-yl)-pyridin-2-yl ester],
[(S)-Methyl-phenyl-carbamic acid 5-(4-isopropyl-5-oxo-2-thioxo-imidazolidin-1-yl)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-tert-butoxymethyl-5-oxo-2-thioxo-imidazolidin-1 -yl)-pyridin- 2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-ferf-butyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[3-(2,2-dimethyl-propyl)-thioureido]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-isopropyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3,3-diethyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-cyclohexyl-thioureido)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-butyl-thioureido)-pyridin-2-yI ester],
[Methyl-phenyl-carbamic acid 5-(3-isobutyl-thioureido)-pyridin-2-yl ester], [Methyl-phenyl-carbamic acid 5-(4-cyano-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-methyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-fluoro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-methoxy-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-methoxy-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3,4-dichlorc-benzoylamino)-pyridin-2~yl ester],
[Methyl-phenyl-carbamic acid 5-(4-methyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-bromo-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-cyano-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-trifluoromethoxy-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(2-fluoro-3Ltrifluoromethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-trifluoromethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3,4-difluoro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-dimethylamino-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-dimethylamino-benzoyIamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-nitro-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-amino-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(3-teAf-butyl-ureido)-pyridin-2-yl ester], [Methyl-phenyl-carbamic acid 5-(4-formyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-morpholin-4-ylmethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-hydroxymethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-chloromethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-(4-piperidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(4-methyl-piperidin-1 -ylmethyl)-benzoyiamino]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(2-ethyl-piperidin-1 -ylmethyl)-benzoylamino]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(2-methyl-piperidin-1 -ylmethyl)-benzoylamino]-pyridin-2-yl ester],
[Methyl-phenyl-carbamic acid 5-[4-(3-methyl-piperidin-1 -yIrnethyl)-benzoyIamino]-pyridin-2-yl ester],
Methyl-phenyl-carbamic acid 5-(4-piperidin-1-yl-benzoylamino)-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-[4-(2~methyl-piperidin-1 -yl)-benzoylamino]-pyridin-2- yl ester,
Methyl-phenyl-carbamic acid 5-[4-(3-methyl-piperidin-1-yl)-benzoylamino]-pyridin-2- yl ester Methyl-phenyl-carbamic acid 5-[4-(4-methyl-piperidin-1-yl)-benzoylamino]-pyridin-2- yl ester
Methyl-phenyl-carbamic acid 4-[4-(2-ethyl-piperidin-1 -yl)-benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(4,4-dimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,6-dimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester Methyl-phenyl-carbamic acid 4-[4-(2,4,6-trimethyl-piperidin-1 -yl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,6-dimethyl-piperidin-1 -ylmethyl)-benzoylamino]- pyridin-2-yl ester Methyl-phenyl-carbamic acid 4-[4-(4,4-dimethyl-piperidin-1-ylmethyl)-benzoylamino]- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 4-[4-(2,4,6-trimethyl-piperidin-1-ylmethyl)- benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-[4-(2-piperidin-1 -yl-ethyl)-benzoylamino]-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2-methyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(3-methyl-piperidin-1-yl)-ethyl]-benzoylamino}- pyridin-2-yl ester Methyl-phenyl-carbamic acid 5-{4-[2-(4-methyl-piperidin-1-yI)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2-ethyl-piperidin-1 -yl)-ethyl]-benzoylamino}- pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(4,4-dimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yI ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2,6-dimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yl ester
Methyl-phenyl-carbamic acid 5-{4-[2-(2,4,6-trimethyl-piperidin-1 -yl)-ethyl]- benzoylamino}-pyridin-2-yl ester
57. A pharmaceutical composition comprising a compound as defined in any one of claims 1-56 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
58. The composition according to claim 57, wherein said composition is in unit dosage form, comprising from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of said compound according to any one of claims 1-56 or pharmaceutically acceptable salt thereof.
59. A pharmaceutical composition for use as a medicament for inhibiting the lipolytic activity of hormone-sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters, said composition comprising a compound according to any one of claims 1-56 or a pharmaceutically acceptable salt thereof together with a pharmaceutically accept- able carrier or diluent.
60. A pharmaceutical composition according to any one of claims 57-59, which is for oral administration.
61. A pharmaceutical composition according to any one of claims 57-59 for nasal, transdermal, pulmonal, or parenteral administration.
62. Use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition.
63. Use of a compound according to any one of claims 1-56 for inhibition of hormone sensitive lipase.
64. Use of a compound according to any one of claims 1-56 for preparation of a pharmaceu- tical composition for inhibition of the lipolytic activity of hormone-sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters.
65. Use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment or prevention of any disorder where it is desirable to
modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and/or
modulate intracellular triacylglycerol and cholesterol ester stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's as well as citrate or malonyl-CoA; and/or
increase insulin sensitivity in adipose tissue, skeletal muscle, liver or pancreatic β cells; and/or modulate insulin secretion from pancreatic β cells.
66. The use according to claim 65, wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 , diabetes type 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism and any combination thereof.
67. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention of dyslipidemia.
68. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention of hyperlipidemia.
69. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention of hyperglycemia.
70. The use of a compound according to any one of claims 1-56 for lowering HbAi0.
71. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention of diabetes type 2.
72. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention impaired glucose tolerance.
73. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention of metabolic syndrome X.
74. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for the treatment and/or prevention of atheroschlerosis.
75. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for delaying or prevention of the progression from impaired glucose tolerance to diabetes type 2.
76. The use of a compound according to any one of claims 1-56 for the preparation of a pharmaceutical composition for delaying or prevention of the progression from non-insulin requiring diabetes type 2 to insulin requiring diabetes type 2.
77. The use according to any one of claims 62-76, wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is used.
78. The use according to any one of claims 62-77, wherein metformin is also used.
79. A method of treating a disorder of a patient where modulation of the activity of hormone- sensitive lipase is desired, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-56 or a pharmaceutically acceptable salt thereof.
80. A method of treating a disorder of a patient where lowering of the activity of hormone- sensitive lipase is desired, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-56 or a pharmaceutically acceptable salt thereof.
81. The method according to any one of claims 79-80, wherein said administration is carried out by the oral, nasal, transdermal, pulmonal, or parenteral route.
82. The method according to any one of claims 79-81 , wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 , diabetes type 2, metabolic syn- drome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, atheroschlerosis, hypertension, abnormalities of lipoprotein metabolism and any combination thereof.
83. The method according to any one of claims 79-82, wherein the therapeutically effective amount of the compound is from about 0.05 to about 2000 mg, preferably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of said compound per day.
84. The method according to any one of claims 79-83, wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is administered to the patient.
85. The method according to any one of claims 79-84, wherein metformin is also administered to the patient.
86. A process for the preparation of a compound according to any one of claims 1-52 or its pharmaceutically acceptable salt, which comprises reacting the appropriate alcohol with the appropriate carbamoylating reagent in a solvent according to the reaction scheme P1
and isolating the disubstituted carbamate product.
87. The process according to claim 86, wherein said carbamoylating reagent
is selected from the group consisting of
88. The process according to any one of claims 86-87, wherein said solvent is selected from the group consisting of tetrahydrofurane, dimethylformamide and N-methylpyroiidone.
89. The process according to any one of claims 86-88, wherein said base is selected from the group consisting of triethylamine, N,N-diisopropyl-N-ethylamine and DABCO.
90. A process for the preparation of a compound according to any one of claims 1-52, said process comprising the treatment of the appropriate amine with the appropriate acylating reagent in a solvent and in the presence of a base according to the reaction scheme P2 and isolating the disubstituted carbamate
91. The process according to claim 90, wherein Lv is Cl.
92. The process according to any one of claims 90-91, wherein said solvent is selected from the group consisting of diethyl ether, tetrahydrofuran and dichloromethane.
93. The process according to any one of claims 90-92, wherein said base is selected from the group consisting of trimethylamine, triethylamine, ethyl-diisopropyl-amine and 1 ,4- diazabicyclo[2.2.2]octane.
94. The process according to any one of claims 90-93, wherein said base is present as a functionality in one or both of the substituents R3 and R4, thus forming a salt with the acid H- Lv.
95. A compound according to any one of the preceeding claims, wherein said compound is selected from the group consisting of
Methyl-phenyl-carbamic acid 5-(4-dimethylaminomethyl-benzoylamino)-pyridin-2-yl es- ter.Methyl-phenyl-carbamic acid 5-(4-diethylaminomethyl-benzoylamino)-pyridin-2-yl es- ter.Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-dipropylaminomethyl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-pyrrolidin-1-ylmethyl-benzoylamino)-pyridin-2-yl ester,
c/s-Methyl-phenyl-carbamic acid 5-[4-(2,6-dimethyl-piperidin-1 -ylmethyl)-benzoylamino]- pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[4-(4-oxo-piperidin-1-ylmethyl)-benzoylamino]-pyridin-2-yl ester,
c/s-Methyl-phenyl-carbamic acid 5-[4-(2,6-dimethyI-morpholin-4-ylmethyl)-benzoylamino]- pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-thiomorpholin-4-ylmethyl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[3-(2-hydroxy-1 ,1 -dimethyl-ethyl)-thioureido]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[3-(1-methyl-cyclopropyl)-thioureido]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[3-(1-methyl-cyclobutyl)-thioureido]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-imidazol-1-yl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-diethylamino-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(4-[1 ,2,4]triazol-1-yl-benzoylamino)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(3,3-dipropyl-thioureido)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-(3,3-dibutyl-thioureido)-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[(piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester,
Methyl-phenyl-carbamic acid 5-[(4-methyl-piperidine-1-carbothioyl)-amino]-pyridin-2-yl ester, Methyl-phenyl-carbamic acid 5-[(4,4-dimethyl-piperidine-1 -carbothioyl)-amino]-pyridin-2-yl ester,
(4-Bromo-phenyl)-methyl-carbamic acid 414-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyI-6'-yI ester,
(4-Chloro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1.S'ppyridinyl-θ'-yl ester,
(3)4-DichIoro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5)6-tetrahydro-2H- [1.S'jbipyridinyl-θ'-yl ester,
(3-Chloro-phenyl)-methyI-carbamic acid 4,4-dimethyI-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1.S'lbipyridinyl-β'-yl ester,
Methyl-p-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6l- yl ester,
(3-Fluoro-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
Methyl-m-tolyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H-[1 ,3']bipyridinyl-6'- yl ester,
(4-Methoxy-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2/-/- [1 ,3']bipyridinyl-6'-yl ester,
(3-Methoxy-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
Methyl-(3-trifIuoromethyl-phenyl)-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2H-[1 ,3']bipyridinyl-6'-yl ester,
(3-Bromo-phenyl)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester, (4-Fluoro-phenyI)-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro-2H- [1 ,3']bipyridinyl-6'-yl ester,
[4-(2-Hydroxy-ethyl)-phenyl]-methyl-carbamic acid 4,4-dimethyl-2,6-dioxo-3,4,5,6-tetrahydro- 2/7-[1.S'lbipyridinyl-β'-yl ester,
EP04736303A 2003-06-12 2004-06-08 Pyridinyl carbamates as hormone-sensitive lipase inhibitors Withdrawn EP1636205A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300879 2003-06-12
US47852603P 2003-06-13 2003-06-13
PCT/DK2004/000391 WO2004111031A1 (en) 2003-06-12 2004-06-08 Pyridinyl carbamates as hormone-sensitive lipase inhibitors

Publications (1)

Publication Number Publication Date
EP1636205A1 true EP1636205A1 (en) 2006-03-22

Family

ID=33553690

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04736303A Withdrawn EP1636205A1 (en) 2003-06-12 2004-06-08 Pyridinyl carbamates as hormone-sensitive lipase inhibitors

Country Status (10)

Country Link
EP (1) EP1636205A1 (en)
JP (1) JP2006527210A (en)
KR (1) KR20060017791A (en)
AU (1) AU2004247319A1 (en)
BR (1) BRPI0411255A (en)
CA (1) CA2526204A1 (en)
MX (1) MXPA05013224A (en)
NO (1) NO20060168L (en)
RU (1) RU2337908C2 (en)
WO (1) WO2004111031A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
JP2008530173A (en) * 2005-02-15 2008-08-07 ノボ ノルディスク アクティーゼルスカブ Methylphenylcarbamic acid 5- (4-isobutyl-2,6-dioxopiperazin-1-yl) pyridin-2-yl esters and salts as hormone sensitive lipase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR20080090381A (en) * 2005-08-29 2008-10-08 제라드 엠. 하우지 Theramutein modulators
AR059826A1 (en) * 2006-03-13 2008-04-30 Univ California UREA INHIBITORS CONFORMATIONALLY RESTRICTED OF SOLUBLE HYDROLASSE EPOXIDE
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
DK2368550T3 (en) 2006-03-27 2013-09-30 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
DE602007012299D1 (en) * 2006-09-21 2011-03-10 Piramal Live Science Ltd PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLISM INTERACTIONS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA
FR2912404B1 (en) 2007-02-09 2009-04-10 Sanofi Aventis Sa AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
UY31432A1 (en) 2007-10-26 2009-05-29 DIARILHIDANTOINE COMPOUNDS
MX2011011964A (en) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders.
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
SG10201501202TA (en) 2010-02-16 2015-04-29 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
PT3738434T (en) 2011-12-28 2023-11-13 Global Blood Therapeutics Inc Intermediates to obtain substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (en) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
ES2836424T3 (en) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrogens to treat castration-resistant and non-metastatic prostate cancer
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (en) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (en) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc COMPOUNDS AND THEIR USES TO MODULATE HEMOGLOBIN
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA033555B1 (en) 2013-03-15 2019-10-31 Global Blood Therapeutics Inc Pharmaceutical compositions for treating sickle cell disorder
UA121299C2 (en) 2013-04-12 2020-05-12 Общєство С Огранічєнной Отвєтствєнностью "Фармінтерпрайсез" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
UA119247C2 (en) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Spirocyclic compounds as tryptophan hydroxylase inhibitors
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
MY189995A (en) 2014-02-07 2022-03-22 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
AR108435A1 (en) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE
TWI778983B (en) 2016-10-12 2022-10-01 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
ES2966707T3 (en) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Hemoglobin modulators for the treatment of sickle cell disease
AU2019378907A1 (en) 2018-11-14 2021-06-03 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (TPH1) for treating diseases or disorders associated with peripheral serotonin
DK3880654T3 (en) 2018-11-19 2022-03-07 Global Blood Therapeutics Inc 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUND WHICH IS ABLE TO MODULATE HEMOGLOBIN

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10010968A1 (en) * 2000-03-07 2001-09-13 Aventis Pharma Gmbh New 5-alkoxy-3-phenyl-3H-1,3,4-oxadiazol-2-one derivatives, are hormone-sensitive lipase inhibitors useful for treating metabolic disorders such as non-insulin dependent diabetes mellitus
WO2001087843A1 (en) * 2000-05-15 2001-11-22 Novo Nordisk A/S Compounds for treating disorders where a decreased level of plasma ffa is desired
WO2003051841A2 (en) * 2001-12-14 2003-06-26 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004111031A1 *

Also Published As

Publication number Publication date
RU2005137716A (en) 2006-05-27
AU2004247319A1 (en) 2004-12-23
KR20060017791A (en) 2006-02-27
JP2006527210A (en) 2006-11-30
CA2526204A1 (en) 2004-12-23
RU2337908C2 (en) 2008-11-10
BRPI0411255A (en) 2006-08-01
MXPA05013224A (en) 2006-03-09
NO20060168L (en) 2006-03-10
WO2004111031A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
EP1636205A1 (en) Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US20060160820A1 (en) Substituted piperazine carbamates
US7279470B2 (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US20060160851A1 (en) Substituted piperidine carbamates
EP1853585A1 (en) 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
US20060160819A1 (en) Substitued piperazine carbamates
US20060160865A1 (en) Pyridinyl carbamates
US20060148799A1 (en) Substituted p-phenyl carbamates
EP1636188A1 (en) Para-substituted phenyl carbamates as inhibitors of hormone sensitive lipase
US20060148860A1 (en) Substituted p-phenyl carbamates
EP1636201A1 (en) Para-substituted phenyl carbamates as inhibitors of hormone sensitive lipase
EP1853580A1 (en) Methylphenylcarbamic acid 5-(4-isobutyl-2,6,-dioxopiperazin-1-yl)pyridinyl-2-yl ester and salts as hormone sensitive lipase inhibitors
TW200305567A (en) Compounds and use thereof for decreasing activity of hormonesensitive lipase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100105